

## CURRICULUM VITAE

Michael D. Reed, Pharm.D., FCCP, FCP

(b) (6)

(b) (6)

### Personal Data:

Date of Birth: (b) (6)

Birthplace: (b) (6)

Marital Status: (b) (6)

Citizenship: (b) (6)

### Faculty Appointments:

2008 – present, Professor of Pediatrics, School of Medicine, Northeast Ohio Medical University, Rootstown, Ohio

1996 – 2007, Professor of Pediatrics (with tenure), Department of Pediatrics, Division of Pediatric Pharmacology and Critical Care, Case Western Reserve University School of Medicine, Cleveland, Ohio.

1991 – 1996, Associate Professor of Pediatrics (with tenure), Department of Pediatrics, Division of Pediatric Pharmacology and Critical Care, Case Western Reserve University School of Medicine, Cleveland, Ohio.

1989 – 1991, Associate Professor of Pediatrics, Department of Pediatrics, Division of Pediatric Pharmacology and Critical Care, University of Virginia School of Medicine, Charlottesville, Virginia.

1988 – 1989, Associate Professor of Pediatrics, Department of Pediatrics, Division of Pediatric Pharmacology and Critical Care, Case Western Reserve University School of Medicine, Cleveland, Ohio.

1982 – 1988, Assistant Professor of Pediatrics, Department of Pediatrics, Division of Pediatric Pharmacology and Critical Care, Case Western Reserve University School of Medicine, Cleveland, Ohio.

1981 – 1982, Senior Clinical Instructor, Department of Pediatrics, Division of Pediatric Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio.

1979 – 1981, Clinical Instructor, Department of Pediatrics, Division of Pediatric Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio.

1981 – 1983, Instructor, Respiratory Therapy Division, Cuyahoga Community College, Cleveland, Ohio.

1981 – 1983, Instructor, Department of Podiatric Medicine, Division of Clinical Sciences, Ohio College of Podiatric Medicine, Cleveland, Ohio.

**Adjunct Faculty Appointments:**

2010 – 2014, Adjunct Professor of Pharmacology, Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio.

2002 – Present, Clinical Professor, Department of Pharmacy Practice, Raabe College of Pharmacy, Ohio Northern University.

1994 – 2002, Clinical Associate Professor of Pharmacy Practice, Raabe College of Pharmacy, Ohio Northern University and Director, Experimental Programs for Northern Ohio.

1990 – 1991, Assistant Clinical Professor, Department of Pharmacy and Pharmaceutics, Medical College of Virginia, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia.

1980 – 1983, Adjunct Assistant Professor of Clinical Pharmacy, College of Pharmacy, University of Toledo, Toledo, Ohio.

**Hospital Appointments**

2010 – 2015, Director, Rebecca D. Considine Research Institute, Akron Children's Hospital, Akron, Ohio.

2007 – 2015, Director, Division of Clinical Pharmacology and Toxicology, Akron Children's Hospital, Akron, Ohio.

2007 – 2015 Associate Chairman, Department of Pediatrics, Akron Children's Hospital, Akron, Ohio

2007 – 2010, Director, Clinical Research Center, Akron Children's Hospital, Akron, Ohio.

2005 – 2007, Co-Chair, Rainbow Babies and Children's Hospital Pharmacy and Therapeutics Committee.

1991 – 2007, Director, Greater Cleveland Poison Control Center, Rainbow Babies and Children's Hospital, University Hospitals of Cleveland, Cleveland, Ohio.

1991 – 2007, Director, Pediatric Clinical Pharmacology and Toxicology, Division of Pediatric Pharmacology and Critical Care, Rainbow Babies and Children's Hospital, Cleveland, Ohio.

2001 – 2007, Member, General Clinical Research Center Scientific Advisory Committee, Case Western Reserve University School of Medicine, Cleveland, Ohio.

1992 – 2007, University Hospitals of Cleveland, Pharmacy and Therapeutics Committee: (member); Formulary Review Subcommittee (member); Anti-Infective Utilization Subcommittee (member); Biotechnology Subcommittee (secretary); Quality Assurance / Drug Utilization Review Subcommittee (member).

1992 – 1999, University Hospitals of Cleveland, Rainbow Babies and Children's Hospital, Safety Committee.

1989 – 1991, Associate Clinical Pharmacist, Department of Pharmacy Services, University of Virginia Medical Center, Charlottesville, Virginia.

1988 – 1989, (member) Nutrition Support Committee, The University Hospitals of Cleveland, Cleveland, Ohio.

1987 – 1989, (member) UH Hazardous Material Subcommittee, Case Western Reserve University School of Medicine, Cleveland, Ohio.

1981 – 1989, Co-Director, Greater Cleveland Poison Control Center, Department of Pediatrics, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, Ohio.

1981 – 1989, Associate Clinical Pharmacist, Department of Pharmacy Services, University Hospitals of Cleveland, Cleveland, Ohio.

1977 – 1981, Pediatric Clinical Pharmacist, Rainbow Babies and Children’s Hospital, Department of Pharmacy Services, University Hospitals of Cleveland, Cleveland, Ohio.

1977 – 1981, (member) Pediatric Hyperalimentation Committee, University Hospitals of Cleveland, Cleveland, Ohio.

1978 – 1981, (member) Bone Marrow Transplantation Committee, University Hospitals of Cleveland, Cleveland, Ohio.

**Education:**

- (b) (6) Doctor of Pharmacy, College of Pharmacy, University of Cincinnati, Cincinnati, Ohio.
- (b) (6) Resident in Pediatric Clinical Pharmacy/Clinical Pharmacology, Children’s Hospital Medical Center, Cincinnati, Ohio.
- (b) (6) Bachelor of Science in Pharmacy, College of Pharmacy, University of Cincinnati, Cincinnati, Ohio.
- (b) (6) Internship in Hospital Pharmacy, Holmes Hospital, Cincinnati, Ohio.
- (b) (6) Internship in Community Pharmacy, Winton Place Pharmacy, Cincinnati, Ohio.

**Licensure, Board and other Certifications:**

1. Certificate program in: “Principles of Clinical Pharmacology,” National Institutes of Health Clinical Center, April 2008 and April 2011
2. Certificate Program in Pediatric Asthma: Ohio Northern University, June, 2004
3. Diplomat, American Board of Clinical Pharmacology, Inc., Certification in Applied Pharmacology, Certificate (b) (6) By examination July, 2003
4. Certificate Program in: Pediatric Diabetes Mellitus, Ohio Northern University, April, 2003
5. Certificate Program in: Palliative Care, Ohio Northern University, June, 2000
6. Ohio State Board of Pharmacy, License No. (b) (6) By examination June, 1975

**Professional Organizations:**

American Board of Clinical Pharmacology  
2006 – 2008 (member)

Board of Pharmaceutical Specialties, American Pharmaceutical Association  
2013 – Present, (member) Specialty Council on Pediatric Pharmacy (inaugural member)  
2011 – 2012, (member) Pediatric Pharmacy Role Delineation Task Force  
2004 – 2010, (member) Specialty Council on Nutrition Support Pharmacy Practice  
1989 – 1990, (member) Specialty Council on Nutrition Support Pharmacy practice

Society for Pediatric Research  
2002 – Present, (Senior member)  
1989 – 2002, (member)  
1994, 1997, 2012 Abstract Review (Annual meeting)

American College of Clinical Pharmacology (FCCP)  
2014- Present (member) Program Planning Committee  
2013- 2014, Member, Nominations Committee  
2010 – 2012, Immediate Past President  
2008 – 2010, President  
2006 – 2008, President-Elect (by election)  
2005 – 2007, Member, ACCP Foundation Committee  
2004 – 2006, Counselor to the President, Executive Committee  
1999 – 2004, Secretary, Member Executive Committee (by election)  
1998 – 2004, Member, Board of Regents (by election)  
1994 – 1996, President, Ohio Chapter American College of Clinical Pharmacology  
1987 – Present, Fellow (FCCP)

American College of Clinical Pharmacy Research Institute

- 2005 – 2007, Chairperson, Research Institute Board of Trustees (by election)
- 2004 – 2005, Research Institute Board of Trustees (member by election)
- 1988 – 1990, Research Institute Board of Trustees (member by election)

American College of Clinical Pharmacy, (FCCP)

- 1987 – 1988, Chairman, Annual Meeting Abstract Review Committee
- 1987 – 1988, Program Committee
- 1986 – 1987, Chairman, Program Planning Committee, Regional Spring Symposium
- 1986 – Present, Fellow (FCCP, by election)
- 1984 – 1985, Budget & Finance Committee
- 1984 – Present, Abstract Review (Annual Meeting)
- 1983 – 1986, (member)

American Society for Clinical Pharmacology and Therapeutics

- 1984 – Present, (member)
- 2003 – 2006, Member, Membership Committee
- 1984 – 1988, 2000, 2004 Abstract Review (Annual meeting)

American Society for Parenteral and Enteral Nutrition

- 1981 – 1991, (member)
- 1988 – 1990, Chairman, Pharmacists Committee, member, Board of Directors (by election)
- 1988 – 1989, Ohio Society PEN, Board of Directors
- 1987 – 1988, Nominations Committee
- 1986 – 1988, Public Policy Committee
- 1984 – 1987, Pharmacists Committee (by election)
- 1984 – 1986, Publications Committee

American Society of Hospital Pharmacists

- 1975 – Present, (member)
- 1988 – 1993, (member) Fellowship Selection Panel ASHP Research and Education Foundation
- 1987 – 1988, (member) ID Fellowship Pharmacotherapy Selection Panel
- 1979 – 1987, Abstract Review (Annual Midyear Clinical Meeting): 2011, 2012

American Association of Colleges of Pharmacy

- 1994 – 1997, (member)

Society of Infectious Diseases Pharmacists

- 1990 – 2002, (member)
- 1992 – 1994, Awards Committee

Society of Critical Care Medicine

- 1990 – 2002, (member)

Virginia Society of Hospital Pharmacists

- 1990 – 1991, (member)
- 1990 – 1992, Education Committee

American Association of Pharmaceutical Scientists

- 1986 – 1992, (member)

Ohio Association of Poison Control Centers

- 1984 – 1989, (member)
- 1984 – 1987, Vice Chairman



American Association of Poison Control Centers  
1982 – 2007, (member)  
1984 – Abstract Review (Annual Meeting)

Cleveland Society of Hospital Pharmacists  
1977 – 1989, (member)

**Special Grants, Awards and Activities:**

1. 2012, September – Nathaniel T. Kwit Memorial Distinguished Service Award, American College of Clinical Pharmacology. “Dr. Reed is receiving this award for his contributions to the field, as well as service to the College.”
2. 2011 – present – US Food and Drug Administration( FDA), Pediatric Advisory Committee, member
3. 2011 – present – US Food and Drug Administration temporary expert Committee member: Gastrointestinal Drugs Advisory Committee (x2), Pharmaceutical Science and Clinical Pharmacology Advisory Committee (x2), Nonprescription Drugs Advisory Committee (x1)
4. 2010, December – Elected Distinguished Practitioner, National Academies of Practice (NAP) in Pharmacy
5. 2010, October – Stevens Distinguished Visiting Professor, Pediatric Clinical Research Unit, The University of Tennessee, Clinical and Translational Science Institute, Le Bonheur Children’s Medical Center, Memphis, TN.
6. 2010 , October – Sumner J. Yaffe, MD, Lifetime Achievement Award in Pediatric Pharmacology, The PPAG. “In recognition of significant and sustained contributions toward the improvement of children’s health through the expansion of the field of pediatric pharmacology and therapeutics.”
7. 2010, September – Special Government Employee
8. 2012 – present (member) – Hattie Larlham Center for Children with Disabilities, Hattie Larlham Community Services, Board of Directors -2015-Present Secretary
9. 2009 – 2012, Chair, Hattie Larlham Center for Children with Disabilities Research Institute Board of Trustees, Member of the Board Executive Committee.
10. 2008 – 2009 (member), Hattie Larlham Center for Children with Disabilities Research Institute’s Professional Advisory Board
11. 2007, June – Robert J. DeSalvo Distinguished Alumnus Award, University of Cincinnati, College of Pharmacy
12. 2005 Honorary Regent (status for life by unanimous vote), American College of Clinical Pharmacology
13. 2004 Ephraim G. Slease Award, AZO Eta Chapter, Cincinnati, Ohio
14. National Institutes of Health/NICHHD, Pediatric Pharmacology Research Unit Network, Investigator (1994 – 2007)
15. National Institutes of Health/NHLBI, National Asthma Education and Prevention Program: Asthma and Pregnancy Guideline Working Group. Subcommittee Chair (2002 – 2005)
16. External Reviewer, Canadian Institutes of Health Research
17. External Reviewer – Thrasher Research Fund

18. Expert Committee – Pediatrics, United States Pharmacopeia, 2000 – 2006
19. Food and Drug Administration, Orphan Products Development Grant (FD-R-000852-04) Propofol Sedation for Acutely Ill Ventilated Children, April 1, 1996 through March 31, 1999, \$298,024 (Direct) (principal investigator)
20. Food and Drug Administration, Orphan Products Development Grant (FD-R-000852-01). Propofol Sedation for Acutely Ill Ventilated Children, September 30, 1992 through September 29, 1995, \$291,696.00 (Direct) and October 1, 1995 – March 30, 1996, \$24,000 (Direct)
21. Tenure, Case Western Reserve University School of Medicine, 1991-2007
22. Ohio Department of Health, Poison Prevention and Treatment Center Grant, July 1991 – 2007, annually
23. External Reviewer, National Research Foundation, South Africa and New Zealand
24. Ohio Department of Health, Ohio Poison Control Network Advisory Committee (member) January 1992 – 1995
25. Fellow, American College of Clinical Pharmacology (FCP), October, 1987
26. Fellow, American College of Clinical Pharmacy (FCCP), July, 1986
27. American Association of Poison Control Centers Annual Research Grant, 1985. An Evaluation of Warning Labels for Hazardous Consumer Products, \$1,000
28. (b) (4), Drug Use in the Elderly Part II, 1985 – 1986, \$(b) (4)
29. (b) (4) Drug Use in the Elderly Part I, 1984 – 1985, \$(b) (4)
30. Medical Consultant, Cleveland Lead Poison Center, City of Cleveland Health Department, 1982 – 1989; 1991 – 1995
31. (b) (4) 1981 – 1983. (b) (4)  
(b) (4), \$(b) (4)
32. (b) (4) 1980, (b) (4)  
(b) (4) \$(b)
33. (b) (4) 1975, (b) (4)  
(b) (4), \$(b)

**Bibliography:**

1. Reed MD, Perry EB, Fennell SJ, Brissie EO Jr and Ball WD. Antibiotic Compatibility and Stability in a Parenteral Nutrition Solution. *Chemotherapy* 1979;25:336-345.
2. Reed MD, Halpin TC Jr, Herzig RH and Gross S. Cyclic Parenteral Nutrition During Allogeneic Bone Marrow Transplantation. *J Parenteral Enteral Nutr* 1981;5:37-39.
3. Bertino JS Jr, Willis ED, Reed MD and Speck WT. Salicylate Hepatitis: A Complication of Kawasaki's Disease. *Am J Hosp Pharm* 1981;38:1171-1172.

4. Reed MD, Bertino JS Jr and Halpin TC Jr. Use of Intravenous Iron Dextran Injection in Children Receiving Total Parenteral Nutrition. *Am J Dis Child* 1981;135:829-831.
5. Reed MD, Vermeulen MW, Stern RC, Cheng PW, Powell SH and Boat TF. Are Measurements of Urine Enzymes Useful During Aminoglycoside Therapy? *Ped Res* 1981;15:1234-1239.
6. Bertino JS Jr, Reed MD, Lambert PO and Halpin TC Jr. Stability of an Extemporaneous Formulation of Injectable Cholecalciferol. *Am J Hosp Pharm* 1981;38:1932-1933.
7. Reed MD, Bertino JS Jr and Blumer JL. Carbamazepine Associated Exfoliative Dermatitis. *Clin. Pharm* 1982;1:78-79.
8. Halpin TC Jr, Bertino JS Jr, Rothstein FC, Kurcznski EM and Reed MD. Iron-Deficiency Anemia in Childhood Inflammatory Bowel Disease: Treatment with Intravenous Iron-Dextran. *J Parenter Enter Nutr* 1982;6:9-11.
9. Ohning BL, Reed MD, Doershuk CF and Blumer JL. Ticarcillin-Associated Granulocytopenia *Am J Dis Child* 1982;136:645-646.
10. Lass JH, Lazarus HM, Reed MD and Herzig RH. Topical Corticosteroid Therapy for Corneal Toxicity from Systematically Administered Cytarabine. *Am J Ophthal* 1982;94:617-621.
11. Reed MD, Lazarus HM, Herzig RH, Halpin TC Jr, Gross S, Husak MP and Blumer JL. Cyclic Parenteral Nutrition During Bone Marrow Transplantation in Children. *Cancer* 1983;51:15630-1570.
12. Reed MD, Aronoff SC, Myers CM, Husak MP, Bertino JS Jr and Blumer JL. Developmental Pharmacokinetics of Moxalactam. *Antimicrob Agents Chemother* 1983;24:383-387.
13. Kercksmar CM, Stern RC, Reed MD, Myers CM, Murdell D and Blumer JL. Ceftazidime in Cystic Fibrosis: Pharmacokinetics and Therapeutic Response. *J Antimicrob Chemother* 1983;12 (Suppl):289-295.
14. Aronoff SC, Murdell D, O'Brien CA, Klinger JD, Reed MD and Blumer JL. Efficacy and Safety of Ceftriaxone in Serious Pediatric Infections. *Antimicrob Agents Chemother* 1983;24:663-666.
15. Reed MD, ReKate HL, Aronoff SC, Myers CM and Blumer JL. Single Dose Plasma and Cerebrospinal Fluid Pharmacokinetics of Ceftriaxone in Infants and Children. *Clin Pharm* 1983;2:558-563.
16. Reed MD, Stern RC, Bertino JS Jr, Myers C, Yamashita TS and Blumer JL. Dosing Implications of the Rapid Elimination of Trimethoprim-Sulfamethoxazole in Patients with Cystic Fibrosis. *J Pediatr* 1984;104:303-307.
17. Aronoff SC, Reed MD, O'Brien CA and Blumer JL. Comparison of the Efficacy and Safety of Ceftriaxone to Ampicillin / Chloramphenicol in the Treatment of Childhood Meningitis. *J Antimicrob Chemother* 1984;13:143-151.
18. Reed MD, Stern RC, Yamashita TS, Ackers I, Myers CM and Blumer JL. Single Dose Pharmacokinetics of Cefsulodin in Patients with Cystic Fibrosis. *Antimicrob Agents Chemother* 1984;25:579-581.
19. Aronoff SC, Soles PV, Reed MD, Kelle F, Husack MP and Blumer JL. Evaluation of Latamoxef as Initial Therapy of Bone and Joint Infections in Childhood. *Chemother* 1984;30:337-344.
20. Reed MD, O'Brien CA, Aronoff SD, Klinger JD and Blumer JL. Ceftazidime as Initial Therapy for Suspected Bacterial Infections in Hospitalized Pediatric Patients. *Antimicrob Agents Chemother* 1984;26:318-321.
21. Bertino JS Jr, Reed MD and Halpin TC Jr. Prophylaxis and Treatment of Childhood Rickets with Parenteral Cholecalciferol. *J Parenter Enter Nutr* 1984;8:556-559.

22. Reed MD, Aronoff SC and Blumer JL. Pediatric Infections. *Drug Intell Clin Pharm* 1984;18:723-726.
23. Reed MD, Stern RC, O'Brien CA, Yamashita TS, Myers CM and Blumer JL. Pharmacokinetics of Imipenem and Cilastatin in Patients with Cystic Fibrosis. *Antimicrob Agents Chemother* 1985;27:583-588.
24. Reed MD. Evaluation of Antibiotics for Home Care Programs. *Drug Intell Clin Pharm* 1985;19:288-290.
25. Blumer JL, Aronoff SC, Myers CM, O'Brien C, Klinger JD and Reed MD. Pharmacokinetics and Cerebrospinal Fluid Penetration of Ceftazidime in Children with Meningitis. *Dev Pharmacol Ther* 1985;8:219-231.
26. Blumer JL, Rothstein FC, Kaplan BS, Yamashita TS, Eshelman FN, Myers CM and Reed MD. Pharmacokinetic Determination of Ranitidine Pharmacodynamics in Pediatric Ulcer Disease. *J Pediatr* 1985;107:301-306.
27. Jaffe AC, O'Brien CA, Reed MD and Blumer JL. Randomized Comparative Evaluation of Augmentin and Cefaclor in Pediatric Skin and Soft Tissue Infections. *Curr Ther Res* 1985;38:160-168.
28. Blumer JL, Stern RC, Klinger JD, Yamashita TS, Myers CM, Blum A and Reed MD. Ceftazidime Therapy in Cystic Fibrosis Patients with Multi-Drug Resistant Pseudomonas. *Am J Med* 1985;79 (Suppl 2A)37-56.
29. Klein BL, Ashenburg CA and Reed MD. Transdermal Scopolamine Intoxication in a Child. *Ped Emerg Care* 1985;1:208-209.
30. Reed MD, Myers CM, Yamashita TS and Blumer JL. Developmental Pharmacology and Therapeutics of Piperacillin in Gram-Negative Infections. *Dev Pharmacol Ther* 1986;9:102-114.
31. Ohning BL, Reed MD and Blumer JL. Continuous Nasogastric Administration of Activated Charcoal for the Treatment of Theophylline Intoxication. *Ped Pharmacol* 1986;5:241-245.
32. Reed MD, Aronoff SC, Stern RC, Yamashita TS, Myers CM, Friedhoff LT and Blumer, JL. Single Dose Pharmacokinetics of Aztreonam in Children with Cystic Fibrosis. *Ped Pulm* 1986;1:282-286.
33. Reed MD, Stern RC, Myers CM, Klinger JD, Yamashita TS and Blumer JL. Therapeutic Evaluation of Piperacillin for Acute Pulmonary Exacerbations in Cystic Fibrosis. *Ped Pulm* 1987;3:101-109.
34. Reed MD, Stern RD, O'Brien CA, Crenshaw DA and Blumer JL. A Randomized Double-Blind Evaluation of Ceftazidime Dose Ranging in Hospitalized Patients with Cystic Fibrosis. *Antimicrob Agents Chemother* 1987;31:698-702.
35. Goldfarb J, Stern RC, Reed MD, Yamashita TS, Myers CM and Blumer JL. Ciprofloxacin Monotherapy for Acute Pulmonary Exacerbations of Cystic Fibrosis. *Am J Med* 1987;82 (Suppl 41):174-179.
36. Lazarus HM, Reed MD, Spitzer TR, Rabaa MS and Blumer JL. High Dose IV Thiotepa and Cryopreserved Autologous Bone Marrow Transplantation for Therapy for Refractory Cancer. *Cancer Treat Rep* 1987;71:689-695.
37. Goldfarb J, Aronoff SC, Jaffe A, Reed MD and Blumer JL. Sultamicillin in the Treatment of Superficial Skin and Soft Tissue Infections in Children. *Antimicrob Agents Chemother* 1987;31:663-664.
38. Reed MD, Kliegman RM, Weiner JS, Huang M, Yamashita TS and Blumer JL. The Clinical Pharmacology of Vancomycin in Seriously Ill Preterm Infants. *Ped Res* 1987;22:360-363.
39. Lazarus HM, Hartnett ME, Reed MD, Murphy B and Lass JH. Comparison of the Prophylactic Effects of 2-Deoxycytidine and prednisolone for High-Dose Intravenous Cytarabine-Induced Keratitis. *Am J Ophthal* 1987;104:476-480.

40. Dickinson CJ, Reed MD, Stern RC, Aronoff SC, Yamashita TS and Blumer JL. The Effect of Exocrine Pancreatic Function on Chloramphenicol Pharmacokinetics in Patients with Cystic Fibrosis. *Ped Res* 1988;23:388-392.
41. Reed MD, Stern RC, Myers CM, Yamashita TS and Blumer JL. Lack of Unique Ciprofloxacin Pharmacokinetic Characteristics in Patients with Cystic Fibrosis. *J Clin Pharmacol* 1988;28:691-699.
42. Drusano GL, Forrest A, Snyder MJ, Reed MD and Blumer JL. An Evaluation of Optimal Sampling Strategy and Adaptive Study Design. *Clin Pharmacol Ther* 1988;44:232-238.
43. Yamashita TS, Lee HL and Reed MD. A Versatile Computational Method for the Determination of Areas Under the Curve and Moment Curve Following Multidose Intravenous Drug Administration. *Int J Biomed Comput* 1988;23:239-249.
44. Reed MD, Kliegman RM, Yamashita TS, Myers CM and Blumer JL. The Clinical Pharmacology of Imipenem and Cilastatin in Premature Infants During the First Week of Life. *Antimicrob Agents Chemother* 1990;34:1172-1177.
45. Hurlbut JC, Thompson S, Reed MD, Blumer JL, Erenberg A and Leff RD. Influence of Infusion Pumps on the Pharmacologic Response to Nitroprusside. *Crit Care Med* 1991;19:98-101.
46. Reed MD, Gooch WM, Minton S, Tanaka-Kido J, Santos JI, Yamashita TS and Blumer JL. Ceftizoxime Disposition in Neonates and Infants During the First Six Months of Life. *DICP Ann Pharmacotherapy* 1991;25:344-347.
47. Kearns GL, Reed MD, Jacobs RF, Ardite M, Yogev RD and Blumer JL. Single Dose Pharmacokinetics of Ceftibuten (Sch39720) in Infants and Children. *Antimicrob Agents Chemother* 1991;35:2078-2084.
48. Moller JC, Gilman JT, Kearns GL, Sussmane JB, Raszynski A, Wolfsdorf J and Reed MD. Effect of Extracorporeal Membrane Oxygenation on Tobramycin Pharmacokinetics in Sheep. *Crit Care Med* 1992;20:1454-1458.
49. Farrar HC, Herold DA and Reed MD. Acute Valproic Acid Intoxication: Enhanced Drug Clearance with Oral Activated Charcoal. *Crit Care Med* 1993;21:299-301.
50. Reed MD and Marx CM. Ondansetron for Treating Nausea and Vomiting in the Poisoned Patient. *Ann Pharmacother* 1994;28:331-333.
51. Nutman J, Brooks LJ, Deakins KM, Baldesare KK, Witte MK and Reed MD. Racemic vs l-epinephrine Aerosol in the Treatment of Post-Extubation Laryngeal Edema: Results from a Prospective, Randomized, Double-Blind Study. *Crit Care Med* 1994;22:1591-1594.
52. Reed MD, Goldfarb J, Yamashita TS, Lemon E and Blumer JL. Single-Dose Pharmacokinetics of Piperacillin and Tazobactam in Infants and Children. *Antimicrob Agents Chemother* 1994;38:2817-2826.
53. Gal PG, Reed MD and Nahata MC. Recent Advances in Pediatrics. *Ann Pharmacother* 1995;29:66-70.
54. Reed MD, Yamashita TS and Blumer JL. Pharmacokinetic-Based Ticarcillin / Clavulanic Acid Dose Recommendations for Infants and Children. *J Clin Pharmacol* 1995;35:658-665.
55. Blumer JL, Reed MD, Kearns GL, Jacobs RF, Gooch WM, Yogev R, Willims K and Ewing BJ. Sequential Single-Dose Pharmacokinetic Evaluation of Meropenem in Hospitalized Infants and Children. *Antimicrob Agents Chemother* 1995;39:1721-1725.
56. Reed, M.D., Yamashita, T.S., Marx, C.M., Myers, C.M. and Blumer, J.L., A Pharmacokinetically Based Propofol Dosing Strategy for Sedation of the Critically Ill, Mechanically Ventilated Pediatric Patient. *Crit Care Med*. 24(9):1473-1481, 1996.

57. Glover ML and Reed MD. Propylene Glycol: The Safe Diluent that Continues to Cause Harm. *Pharmacotherapy* 1996;16:690-693.
58. Glover ML, Kodish E and Reed MD. Continuous Propofol Infusion for the Relief of Treatment-Resistant Discomfort in a Terminally Ill Pediatric Cancer Patient. *J Pediatr Hematol Oncol* 1996;18:377-380.
59. Reed MD, Yamashita TS, Myers CM and Blumer JL. The Pharmacokinetics of Teicoplanin in Children. *J Antimicrob Chemother* 1997;9:789-796.
60. Stevens RC, Reed MD, Shenep JL, Baker DK, Foulds G, Luke DR, Blumer JL and Rodman JH. Pharmacokinetics of Azithromycin Following Single- and Multiple-Dosing in Children. *Pharmacotherapy* 1997;17:874-880.
61. Reed MD, Yamashita TS, Knupp CK, Veazey JM Jr and Blumer JL. The Pharmacokinetics of Intravenously and Intramuscularly Administered Cefepime in Infants and Children. *Antimicrob Agents Chemother* 1996;41:1783-1787.
62. Reed MD. Proactive Solutions to Control the Clinical and Economic Challenges of Antibiotic Therapy: Symposium Introduction. *Ann Pharmacother* 1998;31:S5-S6.
63. Reed MD. Rational Prescribing of Extended-Spectrum Penicillin Beta-Lactamase Inhibitor Combinations: Focus on Ticarcillin / Clavulanic Acid. *Ann Pharmacother* 1998;32:S17-S21.
64. Leff RD, Cho CT, and Reed MD. Safety and Efficacy of Trimethoprim Hydrochloride Solution for the Treatment of Children with Otitis Media. *J Pediatr Pharm Pract* 1998;3:33-39.
65. Kearns GL, van den Anker J, Reed MD and Blumer JL. Pharmacokinetics of Metoclopramide in Neonates. *J Clin Pharmacol* 1998;38:122-128.
66. Lazarus HM, O'Riordan MA, Creger RJ, Blumer JL and Reed MD. A Randomized, Double-Blind Evaluation of Bolus-Dose vs Continuous-Infusion Granisetron in the Prevention of Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation. *Clin Drug Invest* 1999;17:155-165.
67. Findling RL, Reed MD, Myers C, O'Riordan MA, Fiala S, Branicky L, Waldorf B and Blumer JL. Paroxetine Pharmacokinetics in Depressed Children and Adolescents. *J Am Acad Child Adolesc Psychiatry* 1999;38:952-959.
68. Findling RL, Preskorn SH, Marcus RN, Magnus RD, D'Amico MF, Marathe PH and Reed MD. Nefazodone Pharmacokinetics in Depressed Children and Adolescents. *J Am Acad Child Adolesc Psychiatry* 2000;39:1008-1016.
69. Nakamura H, Rose PG, Blumer JL and Reed MD. Acute Encephalopathy Due to Aluminum Toxicity Successfully Treated by Combined Intravenous Deferoxamine and Hemodialysis. *J Clin Pharmacol* 2000;40:296-300.
70. Ten Eick AP and Reed MD. The Hidden Dangers of the Co-Administration of Antibiotics with Digoxin: Focus on Azithromycin. *Curr Ther Res* 2000;61:148-160.
71. Ten Eick AP, Sallee D, Preminger T, Weiss A and Reed MD. Possible Digoxin-Azithromycin Drug Interaction in a Young Child. *Clin Drug Invest* 2000;20:61-64.
72. Bradley JS, Kearns GL, Reed MD, Capparell EV, Vincent J and the PPRU Network. Pharmacokinetics of a Fluoronaphthyridone, Trovafloxacin (CP 99,219) in Infants and Children Following Administration of a Single Intravenous Dose of Alatrofloxacin. *Antimicrob Agents Chemother* 2000;44:1195-1199.
73. Kearns GL, Abdel-Rahman SM, Blumer JL, Reed MD, James LP, Jacobs RF, Welshman IR, Jungbluth GL, Stalker DJ and the PPRU Network. Single Dose Pharmacokinetics of Linezolid in Children. *Pediatr Infect Dis J* 2000;19:1178-1184.

74. Reed MD, Stern RC, O’Riordan MA and Blumer JL. The Pharmacokinetics of Colistin in Patients with Cystic Fibrosis. *J Clin Pharmacol* 2001;41:645-654.
75. Reed MD, Myers CM and Blumer JL. The Influence of Midazolam on the Protein Binding of Ketorolac. *Curr Ther Res* 2001;62:558-565.
76. Reed MD, Rodarte A, Blumer JL, Khoo K-C, Akbari B, Pou S, Kearns GL and the PPRU Network. The Single-Dose Pharmacokinetics of Midazolam and its Primary Metabolite in Pediatric Patients After Oral and Intravenous Administration. *J Clin Pharmacol* 2001;41:1359-1369.
77. Glover ML, Blumer JL and Reed MD. Use of Propofol to Facilitate Extubation in Mechanically Ventilated Children: A Case for Pediatric Trials. *Curr Ther Res* 2002;63:77-90.
78. Nakamura H, Blumer JL and Reed MD. Pemoline Ingestion in Children: A Report of Five Cases and Review of the Literature. *J Clin Pharmacol* 2002;42:275-282.
79. Findling RL, Myers C, O’Riordan MA, Branicky LA, Pettigrew A, Reed MD and Blumer JL. An Open-Label Dosing Study of Paroxetine in Depressed Children and Adolescents. *Curr Ther Res* 2002;63:588-601.
80. Peacock JE Jr, Herrington DA, Wade JC, Lazarus HM, Reed MD, Sinclair JW, Haverstock DC, Kowalsky SF, Hurd DD, Cushing DA, Harmon CP and Conowitz GR. Ciprofloxacin Plus Piperacillin Compared with Tobramycin Plus Piperacillin as Empirical Therapy in Febrile Neutropenic Patients: A Randomized, Double-Blind Trial. *Ann Intern Med* 2002;137:77-86.
81. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD and Rotschafter JC. Synergistic Activity of Colistin and Ceftazidime Against Mult-Antibiotic Resistant *Pseudomonas aeruginosa* in an in vitro Pharmacodynamics Model. *Antimicrob Agents Chemother* 2003;47:905-909.
82. Koren G, Kearns GL, Reed MD and Pons G. Use of Healthy Children as Volunteers in Drug Studies: The Ethical Debate. *Clin Pharmacol Ther* 2003;73:147-152.
83. Kociancic T and Reed MD. Acetaminophen Intoxication and Length of Treatment: How Long is Long Enough? *Pharmacotherapy* 2003;23:1052-1059.
84. Findling RL, McNamara NK, Gracious BL, Youngstrom EA, Stansbrey RJ, Reed MD, Demeter CA, Branicky LA, Fisher KE and Calabrese JR. Combination Lithium and Divalproex in Pediatric Bipolarity. *J Am Acad Child Adolesc Psychiatry* 2003;41:895-901.
85. Findling RL, McNamara NK, O’Riordan MA, Reed MD, Demeter CA, Branicky LA and Blumer JL. An Open-Label Pilot Study of St John’s Wort in Juvenile Depression. *J Am Acad Child Adolesc Psychiatry* 2003;42:908-914.
86. Lebovitz DJ, Smith PG, O’Riordan M and Reed MD. Pharmacokinetic Properties and Tolerability of Single-Dose Terbutaline in Patients with Severe Asthma Treated in the Pediatric Intensive Care Unit . *Curr Ther Res* 2004;65:98-111.
87. Dutta S, Zhang Y, Conway JM, Sallee FR, Biton V, Reed MD and Kearns GL. Divalproex-ER Pharmacokinetics in Older Children and Adolescents. *Pediatr Neurol* 2004;30:330-337.
88. Chung AM and Reed MD. Intentional Topiramate Ingestion in an Adolescent Female. *Ann Pharmacother* 2004;38:1439-1442.
89. Williams CB, Day SD, Reed MD, Copeland EA, Bechtel T, Leather HL, Wingard JR, Abbott BL, Abhyankar S and McGuirk JP. Dose Modification Protocol Using Intravenous Busulfan (Busulfex) and Cyclophosphamide Followed by Autologous or Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Hematologic Malignancies. *Biol Blood Marrow Transplant* 2004;10:614-623.

90. Hooshmand-Rad R, Reed MD, Chu A, Gotz V, Morris JA, Weinberg J and Dominguez EA. Retrospective Study of the Renal Effects of Amphotericin B Lipid Complex When Used at Higher-Than-Recommended Dosages and Longer Durations Compared with Lower Dosages and Shorter Durations in Patients with Systemic Fungal Infections. *Clin Ther* 2004;26:1652-1662.
91. Findling RL, McNamara NK, Gracious BL, O’Riordan MA, Reed MD, Demeter C and Blumer JL, Quetiapine in Nine Youths with Autistic Disorder. *J Child Adolesc Psychopharmacol* 2004;14:287-294.
92. Molloy EJ, Doctor BA, Reed MD and Walsh MC. Perinatal Toxicity of Domestic Naphthalene Exposure. *J Perinatal* 2004;24:792-793.
93. Capparelli EV, Reed MD, Bradley JS, Kearns GL, Jacobs FR, Damle BD, Blumer JL and Grasela DM. Pharmacokinetics of Gatifloxacin in Infants and Children. *Antimicrob Agent Chemother* 2005;49:1106-1112.
94. Findling RL, McNamara NY, Youngstrom EA, Stansbrey R, Gracious BL, Reed MD and Calabrese JR. Double-Blind 18-Month Trial of Lithium vs Divalproex Maintenance Treatment in Pediatric Bipolar Disorder. *J Amer Acad Child Adolesc Psychol* 2005;44:409-417.
95. James LP, Simpson PA, Farrar HC, Kearns GL, Wasserman GS, Blumer JL, Reed MD, Sullivan JE, Hinson JA and the PPRU Network. Cytokines and Toxicity in Acetaminophen Overdose. *J Clin Pharmacol* 2005;45:1165-1171.
96. Blumer JL, Reed MD, Kaplan EL and Drusano GL. Explaining the Poor Bacteriologic Eradication Rate of Single-Dose Ceftriaxone in Group A Streptococcal Tonsillopharyngitis: A Reverse Engineering Solution Using Pharmacodynamic Modeling. *Pediatrics* 2005;116:927-932.
97. Beggs S, Cranswick N and Reed MD. Improving Drug Use for Children in the Developing World, *Arch Dis Child* 2005;90:1091-1093.
98. Seltzer SM, Reed MD and Siwik ES. Intra-Atrial Tissue Plasminogen Activator Infusion for Prosthetic Valve Thrombosis. *Cath Cardiovasc Interv* 2006;67:139-141.
99. Heresi GO, Gertsman DR, Reed MD, van den Anker J, Blumer JL, Kovanda L, Keirns JJ, Buell D and Kearns GL. The Pharmacokinetics of Micafungin, a Novel Echinocandin, in Premature Infants. *Ped Infect Dis J* 2006;25:1110-1115.
100. Findling RL, Reed MD, O’Riordan MA, Demeter CA, Stanbrey RJ and McNamara NK. The Effectiveness, Safety and Pharmacokinetics of Quetiapine in Aggressive Children with Conduct Disorder. *J Am Acad Child Adolesc Psych* 2006;45:792-800.
101. Findling RL, Reed MD, O’Riordan MA, Demeter CA, Stanbrey RJ and McNamara NK. A 26-Week, Open-Label Study of Quetiapine in Children with Conduct Disorder. *J Child Adolesc Psychopharmacol* 2007;17:1-9.
102. Findling RL, McNamara NK, Stansbrey RJ, Gracious BL, Whipkey RE, Demeter CA, Reed MD, Youngstrom EA and Calabrese JR. Combination Lithium and Divalproex Sodium in Pediatric Bipolar Symptom Re-Stabilization. *J Am Acad Child Adolesc Psych* 2006;45:142-148.
103. Findling RL, Frazier TW, Youngstrom EA, McNamara NK, Stansbrey RJ, Gracious BL, Reed MD, Demeter CA and Calabrese JR. Double Blind, Placebo-Controlled Trial of Divalproex Monotherapy in the Treatment of Symptomatic Youth at High Risk for Developing Bipolar Disorder. *J Clin Psycho* 2007;68:781-788.
104. Rubino CM, Capparelli EV, Bradley JW, Blumer JL, Kearns GL, Reed MD, Jacobs R, Cinicione B and Grasela DM. Population Pharmacokinetic Model for Gatifloxacin in Pediatric Patients. *Antimicrob Agents Chemother* 2007;51:1246-1252.

105. Walliser G, Grossberg R and Reed MD. Look-Alike Medications: A Formula for Possible Morbidity and Mortality in the Long-Term Care Facility. *J Am Med Dir Assoc* 2007;9:541-542.
106. Findling RL, Greenhill LL, McNamara NK, Demeter CA, Kotler LA, O’Riordan MA, Myers C and Reed MD. Venlafaxine in the Treatment of Children and Adolescents with Attention Deficit / Hyperactivity Disorder. *J Child Adolescent Psychopharm* 2007;17:433-445.
107. Blumer JL, Reed MD, Steinberg F, O’Riordan MA, Rosen CL, Springer MA, Christensen M, Glaze D and NICHD PPRU Network. Potential Pharmacokinetic Basis for Zolpidem Dosing in Children with Sleep Difficulties. *Clin Pharmacol Ther* 2008;83:551-558.
108. Kearns GL, Blumer JL, Schexnayder S, James LP, Adcock KG, Reed MD, Daniel JF, Gaedigk A and Paul J. Single-Dose Pharmacokinetics of Oral and Intravenous Pantoprazole in Children and Adolescents. *J Clin Pharmacol* 2008;48:1356-1365.
109. Bestic M, Blackford M and Reed MD. Fomepizole: A Critical Assessment of Current Dose Recommendations. *J Clin Pharmacol* 2009;49:130-137.
110. Blumer JL, Findling RL, Shih WJ, Soubrane C and Reed MD. Controlled Clinical Trial of Zolpidem in the Treatment of Insomnia Associated with Attention Deficit Hyperactivity Disorder in Children 6 to 17 Years of Age. *Pediatrics* 2009;123:e770-e776.
111. Findling RL, Pagano ME, McNamara NK, Stansbrey RJ, Faber JE, Lingler J, Demeter CA, Bedoya D and Reed MD. The Short-Term Safety and Efficacy of Fluoxetine in Depressed Adolescents with Alcohol and Cannabis Use Disorders: A Pilot-Randomized Placebo-Controlled Trial. *Child Adolesc Psycho Ment Health* 2009;3:1-13.
112. Pichichero ME and Reed MD. Variations of Pharmacokinetic/Pharmacodynamic (PK/PD) Parameters of Amoxicillin May Explain Treatment Failures in Acute Otitis Media. *Pediatr Drugs* 2009;11:243-249.
113. Blackford M and Reed MD. The Clinical Pharmacology Consult-2 Cases. *eJ Am Coll Osteopath Pediatr* 2009;2.
114. Blackford M, Fitzgibbon J and Reed MD. Assessment of Serum Creatinine Kinase Among Adolescent Patients Following Jimsonweed (*Datura Stramonium*) and Moonflower (*Datura Innoxia*) Ingestions: A Review of 11 Cases. *Clin Toxicol* 2010;48:431-434.
115. Glauser TA, Cnaan A, Shinnas S, Hirtz DG, Diugos D, Masur D, Clark PO, Capparelli EV and Adamson PC. Ethosuximide, valproic acid and lamotrigine in childhood absence epilepsy. *New Engl J Med* 2010; 362:790-799, (member of collaboration).
116. White PC, Baum DL, Ross H, Falletta L and Reed MD. Cocooning: Influenza Vaccine for Patients and Caretakers in an Urban Pediatric Medical Home. *Clin Pediatr* 2010;49:1123-1129.
117. Endimiani A, Blackford M, Dasenbrook EC, Reed MD, Bajaksouszian S, Hujer AJ, Rudin SD, Hujer KJ, Perreten Va, Rice LB, Jacobs MR, Konstan MW and Bonomomo RA. Emergence of Linezolid-Resistant *Staphylococcus aureus* after Prolonged Treatment of Cystic Fibrosis Patients In Cleveland. *Antimicrob Agents Chemother* 2011;55:1684-92.
118. Blackford M, Felter T, Gothard MD and Reed MD. Assessment of the Clinical Use of Intravenous and Oral N-Acetylcysteine in the Treatment of Acute Acetaminophen Poisoning in Children: A Retrospective Review. *Clin Ther* 2011;33:1322-30.
119. Blackford, M, Falletta L, Andrews DA and Reed MD. A Burn Center Paradigm to Fulfill Deferred Consent Public Disclosure and Community Consultation Requirements for Emergency Care Research. *Burns*, 2012;38:807-812.

120. Blackford M, Grossberg R, Gothard M and Reed M. Valproic Acid-Associated Hypoalbuminemia in Medically Fragile Pediatric and Young Adult Patients in a Long Term Care Facility: Potential Mechanisms for Decreased Albumin Synthesis. *Curr Topics Pharmacol* 2012;16:99-105.
121. Depue K, Christopher NC Raed M, Forbes MF, Besunder JB and Reed MD. Efficacy of Intravenous Lidocaine to Alleviate Pain Associated with Propofol Infusion in Pediatric Patients during Procedural Sedation. *Ped Emerg Med*, 2013;29:13-16.
122. Glauser TA, Cnaan A, Shennar S, Hirtz DG, Dlugos D, Clark PD, Adamson PC, and Childhood Absence Epilepsy Study Team. Ethosuximide, Valproic Acid and Lamotrigine in Childhood Absence Epilepsy: Initial Monotherapy Outcomes at 12 Months. *Epilepsia* 2013;54:141-155 (member of study team.)
123. Grossberg R, Blackford ML, Friebert S, Benore E and Reed MD. Direct Care Staff and Parents'/Legal Guardians' Perspectives on End-of-Life Care in a Long-Term Care Facility for Medically Fragile and Intellectually Disabled Pediatric and Young Adult Residents. *Palliat Support Care*, 2013;11:307-314.
124. Blackford ML, Do ST, Enlow TC and Reed MD. Valproic Acid and Topiramate Induced Hyperammonemia Encephalopathy in a Patient with Normal Serum Carnitine: A Case Report. *J Pediatr Pharmacol Ther*, 2013;18:128-136.
125. Reed MD, VanNostran W. Assessing Pain Intensity with the Visual Analogue Scale: A Plea for Uniformity, *J Clin Pharmacol*, 2014; 54:241-244.
126. Bonny, AE, Lange, HLH, Rogers LK, Gothard, DM and Reed, MD. A Pilot Study of Depot Medroxyprogesterone Acetate Pharmacokinetics and Weight Gain in Adolescent Females. *Contraception*, 2014; 89:357-360.
127. Bhattacharyya S, Yan K, Pence L, Simpson PM, Gill P, Letzig G, Beger RD, Sullivan JE, Kearns GL, Reed MD, Marshall JD, Van Den Anker JN, James LP. Targeted Liquid Chromatography-Mass Spectrometry Analysis of Serum Acylcarnitines in Acetaminophen Toxicity in Children. *Biomarker Med*, 2014;8:147-159.
128. (b) (6) Reed, MD. (b) (6) (b) (6) in press.
129. (b) (6) Reed M, (b) (6) in revision
130. (b) (6) Reed, MD. (b) (6) , in revision.
131. (b) (6) Reed MD. (b) (6) in press.

**Invited Reviews and Editorials:**

1. Reed MD, Bertino JS Jr, Aronoff SC, Speck WT and Blumer JL. Evaluation of Moxalactam. *Clin Pharm* 1982;1:125-134.
2. Reed MD and Blumer JL. Clinical Pharmacology of Antitubercular Drugs. *Ped Clin NA* 1983;30:177-193.
3. Blumer JL and Reed MD. Clinical Pharmacology of Aminoglycoside Antibiotics in Pediatrics. *Ped Clin NA* 1983;30:195-208.
4. Blumer JL and Reed MD. Role of Penicillin in the Treatment of Gram Negative Infections in Children. Proceedings of the 13<sup>th</sup> International Congress of Chemotherapy, August 28 – September 2, 1983, Vienna, Austria.

5. Reed MD and Blumer JL. Amoxicillin-Potassium Clavulanate: Rational Pharmacology Meets Clinical Infectious Disease. *Clin Pharm* 1984; 3:653-654 (Editorial).
6. Reed MD. Techniques of Administration of Total Parenteral Nutrition to Patients Receiving Chemotherapy. ASPEN 9<sup>th</sup> Clinical Congress Postgraduate Course on Pediatric Cancer and Nutrition, Miami, Florida, January 1985.
7. Reed MD. Overview of Vitamin Pharmacology. ASPEN 10<sup>th</sup> Clinical Congress Postgraduate Course on Vitamin Physiology in Infants, Dallas, Texas, February 1986.
8. Bertino JS Jr and Reed MD. Barbiturate and Non-Barbiturate Sedative Hypnotic Intoxication in Children. *Ped Clin NA* 1986;33:703-722.
9. Blumer JL, Stern RC, Yamashita TS, Myers CM and Reed MD. Cephalosporin Therapeutics in Cystic Fibrosis. *J Pediatr* 1986;108(5 Pt 2):854-860.
10. Reed MD. Current Concepts in Clinical Therapeutics: Bacterial Meningitis in Infants and Children. *Clin Pharm* 1986;5:798-809.
11. Reed MD. Antimicrobials on the Horizon: Cefixime. *Hosp Ther* 1988;13:14-30.
12. Besunder JB, Reed MD and Blumer JL. Principles of Drug Biodisposition in the Neonate: A Critical Evaluation of the Pharmacokinetic-Pharmacodynamic Interface (Part I). *Clin Pharmacokinet* 1988;14:189-216 (Part II), 261-286.
13. Reed MD and Blumer JL. Urologic Pharmacology in the Office Setting. *Urol Clin NA* 1988;15:737-751.
14. Reed MD. Developmental Pharmacology: Relationship to Drug Use. *Drug Intell Clin Pharm* 1989; (7-8 Suppl):S21-S26.
15. Reed MD and Besunder JB. Developmental Pharmacology: Ontogenic Basis for Drug Disposition. *Ped Clin NA* 1989;36:1053-1074.
16. Kearns GL and Reed MD. Clinical Pharmacokinetics in Infants and Children: A Reappraisal. *Clin Pharmacokinet* 1989;17(Suppl 1):29-67.
17. Usala AL and Reed MD. Clonidine Therapy for Short Stature: Can the Question be Put to Rest. *DICP Ann Pharmacother* 1991;25:1384-1385 (Editorial).
18. Gal P, James C and Reed MD. Indomethacin Therapy for Intraventricular Hemorrhage in Neonates: Another Use for that Old Drug. *DICP Ann Pharmacother* 1991;25:1385-1387 (Editorial).
19. Buck ML and Reed MD. Use of Non-Depolarizing Neuromuscular Blocking Agents in Mechanically Ventilated Patients. *Clin Pharm* 1991;10:32-48.
20. Reed MD, Buck ML and Sutphen JL. Drug Therapy and the Gastrointestinal Tract. *Semin Perinatal* 1992;16:21-31.
21. Reed MD and Blumer JL. Therapeutic Drug Monitoring in the Pediatric Intensive Care Unit. *Pediatr Clin NA* 1994;41:1227-1243.
22. Frazee LA and Reed MD. Warfarin and Nonsteroidal Anti-inflammatory Drugs: Why Not! *Ann Pharmacother* 1995;29:1289-1291 (Editorial).
23. Reed MD. The Ontogeny of Drug Disposition: Focus on Drug Absorption, Distribution and Excretion. *Drug Info Assoc J* 1996;30:1129-1134.
24. Reed MD. Clinical Pharmacokinetics of Amoxicillin and Clavulanate. *Pediatr Infect Dis J* 1996;15 Suppl:949-954.

25. Reed MD and Blumer JL. Azithromycin: A Critical Review of the First Azilide Antibiotic and Its Role in Pediatric Practice. *Pediatr Infect Dis J* 1997;16:1069-1083.
26. Reed MD. The Pathophysiology and Treatment of Cystic Fibrosis. *J Pediatr Pharm Pract* 1997;2:285-308.
27. Findling RL, Schulz SD, Reed MD and Blumer JL. The Antipsychotics: A Pediatric Perspective. *Pediatr Clin NA* 1998;45:1205-1232.
28. Ten Eick AP, Nakamura H and Reed MD. Drug-Drug Interactions in Pediatric Psychopharmacology. *Pediatr Clin NA* 1998;45:1233-1264.
29. Reed MD. The Clinical Pharmacology of Amoxicillin and Clavulanic Acid. *Pediatric Infect Dis J* 1998;17:957-962.
30. Reed MD. A Reassessment of Ticarcillin / Clavulanic Acid Dose Recommendations for Infants, Children and Adults. *Pediatr Infect Dis J* 1998;17:1195-1199.
31. Fink RJ and Reed MD. Contemporary Management of Acute Respiratory Syncytial Virus Bronchiolitis in Hospitalized Infants and Children. *J Pediatr Pharm Pract* 1999;4:13-22.
32. Findling RL, Reed MD and Blumer JL. Pharmacologic Treatment of Depression in Children and Adolescents. *Paediatr Drugs* 1999;1:161-182.
33. Reed MD. Optimal Sampling Theory: An Overview of Its Application to Pharmacokinetic Studies in Infants and Children. *Pediatrics* 1999;104(3 Pt 2):627-632.
34. Volsko T, Reed MD. Drugs Used in the Treatment of Asthma: A Review of Clinical Pharmacology and Aerosol Drug Delivery. *Resp Care Clinics NA* 2000;6:41-56.
35. Ten Eick AP, Reed MD. Clinical Pharmacology Research in the Pediatric Patient: The Challenge Continues. *Prog Pediatr Cardiol* 2000;12:29-35.
36. Ten Eick AP, Blumer JL and Reed MD. Safety of Antihistamines in Children. *Drug Safety* 2001;24:119-147.
37. Blumer JL, Reed MD and Knupp C. Review of the Pharmacokinetics of Cefepime in Children. *Pediatr Infect Dis J* 2001;20:337-342.
38. Reed MD and Bell D. Clinical Pharmacology of Bivalirudin. *Pharmacotherapy* 2002;22(6 Pt2):105S-111S.
39. Reed MD and Findling RL. Overview of Current Management of Sleep Disorders in Children Pharmacotherapy. *Curr Ther Res* 2002;63(Suppl B): B18-B37.
40. Chung AM, Reed MD and Blumer JL. Antibiotics and Breast Feeding: A Critical Review of the Literature. *Paediatr Drugs* 2002;4:817-837.
41. Frattarelli DAC, Reed MD, Giacoia GP and Aranda JV. Antifungals in Systemic Neonatal Candidiasis. *Drugs* 2004;64:949-968.
42. Kociancic T, Reed MD and Findling RL. Evaluation of Risks Associated with Short-and Long-Term Psychostimulant Therapy for Treatment of ADHA in Children. *Exp Opinion Drug Safety* 2004;3:93-100.
43. Naeem N, Reed MD, Creger RJ, Youngner SJ and Lazarus HM. Transfer of the Hematopoietic Stem Cell Transplant Patient to the Intensive Care Unit: Does It Really Matter? *Bone Marrow Transplant* 2006;37:119-133.
44. Bestic M, Reed MD. The ontogeny of human kidney development: Influence on neonatal diuretic therapy. *NeoReviews* 2005;Part I 6:363-368 and Part II 6:392-398.

45. Bertino JS Jr, Greenberg HE and Reed MD. American College of Clinical Pharmacology Position Statement on the Use of Microdosing in the Drug-Development Process. *J Clin Pharmacol* 2007;47:418-422.
46. Abdel-Rahman SM, Reed MD, Wells TG, Kearns GL. Considerations in the Rational Design and Conduct of Phase I / II Pediatric Clinical Trials: Avoiding the Problems and Pitfalls. *Clin Pharmacol Ther* 2007;81:483-494.
47. Figg WD, Chau CH, Okita R, Preusch P, Tracy TS, McLeod H, Reed M, Pieper J, Knoell D, Miller K, Speedie M, Blouin R, Kroboth P, Koda-Kimble MA, Taylor P, Cohen J and Giacomini K. PharmD Pathways to Biomedical Research: The National Institutes of Health Special Conference on Pharmacy Research. *Pharmacotherapy* 2008;28:821-833.
48. Reed MD. Team-Centered Clinical Pharmacology Practice: Is It a Remedy For or the Basis of Our Discipline? *Clin Pharmacol Ther* 2008;83:218-219 (Editorial).
49. Reed MD. Rhabdomyolysis in Pediatrics: Often Discussed, Rarely Observed. *eJ Am College Osteopath Ped* 2009;August;2(4).
50. Reed MD. Drug Disposition in the Newborn Infant: An Overview of important Ontogenic Factors Determining Optimal Pharmacotherapy. *eJ Am Coll Osteopath Pediatr* 2(3), August 2010.
51. Reed MD. Clinical Update: Common Antidotes Used in the Treatment of Childhood Poisonings. *eJ Am Coll Osteopath Pediatr* 2009;October;2(1).
52. Reed MD and Bestic M. Pharmacogenomics in 2011. Navigating the Maze to the Bedside. *eJ Am Coll Osteopath Pediatr*;3(2): Winter, 2011.
53. Reed MD. Reversing the Myths Obstructing the Determination of Optimal Age- and Disease- Based Drug Dosing in Pediatrics. *J Pediatr Pharmacol Ther.* 2011;16:4-13
54. Reed MD. Cough and Cold Medications in Infants and Children: Not! *eJ Am Coll Osteopath Pediatr* Spring 2011.
55. Reed MD. Athletes and Drugs: A Bad Combination. *eJ Am Coll Osteopath Pediatr*, 2011.
56. Giacoia G and Reed MD. In Memoriam Summer J Yaffe: The Father of Pediatric Clinical Pharmacology. *J. Pediatr Pharmacol Ther* 2011; 16:162-166 (Editorial).
57. Reed MD. Sports Drinks, Energy Drinks, and the Beta-2 Receptor Agonists: For Enhanced Performance, Really? *eJ Am Coll Osteopath Pediatr.* 4(4): July, 2012
58. Bestic M, Reed MD. Hypercholesterolemia in Pediatric Practice: Focus on the Statins. *eJ Am Coll Osteopath Pediatr* 4(5): Sept, 2012
59. Blackford M, Reed MD. Vitamin D and Bone Health in Perspective. *eJ Am Coll Osteopath Pediatr* 4(6)Dec, 2012.
60. Bestic M, Reed MD. Common Diuretics Used in the Preterm and Term Infant: What's Changed? *Neo Reviews*, 2012;13:e410-e419.
61. Reed MD. An Update of the Histamine (H1) Receptor Antagonists. *eJ Am Coll Osteopath Pediatr.* 5(4): Summer 2013.
62. Reed, MD. The Balance Between Effective Opioid-Based Pain Management and Patient Safety: Can It Be Achieved? *J. Pediatr Pharmacol Ther.* 2013;18:264-268 (editorial).
63. Reed, MD. Clinical Research in Pediatrics – We Must Sustain the Advocacy (editorial). *eJ Am Coll Osteopath Pediatr, eJ Am Coll Osteopath Pediatr* 6(1):Fall 2013.
64. Reed, MD. Child Abuse and the Substances Involved: An Overview in laboratory-based identification., *eJ Am Coll Osteopath Pediatr.*6(2): Winter 2014.

65. Blackford M, Reed, MD. Clinical Pharmacology Consult: Intentional Iron Overdose: eJ AmColl Osteopath Pediatr. 6(4): Summer 2014.
66. Bestic M., Reed MD. Clinical Challenge: Nicotine Exposure and the e-Cigarette Boom. eJ Am Coll Osteopath Pediatr. 6(4): Summer 2014.
67. (b) (6) and Reed MD. (b) (6) in press (editorial).

### Book Chapters

1. Schrock WA and Reed MD. Drug Formulary in Handbook of Respiratory Care, Lough MD, Chatburn RL, Schrock WA, eds, Yearbook Medical Publishers, Chicago, Illinois, 1983.
2. Blumer JL and Reed MD (editors). Pediatric Toxicology. Ped Clin NA 33 (no 2 & 3), 1986.
3. Besunder JB, Reed MD and Blumer JL. Antimicrobial Disposition in Children with Organ Failure in Antimicrobial Therapy in Infants and Children. Koren G, Prober CG and Golder R, eds, Marcel Dekker, New York, pp 53-68, 1988.
4. Reed MD and Witte MK. Infections of the Lower Respiratory Tract (Chapter 95) in Pharmacotherapy: A Pathophysiologic Approach, DiPiro JT, Talbert RL, Hayes PE, Yee GC, Posey LM, eds. Elsevier Science Publishing Co, New York, pp 1089-1105, 1988.
5. Reed MD, Besunder JB and Blumer JL. Neonatal Clinical Pharmacology: Principles and Practice in Neonatal Respiratory Care, 2<sup>nd</sup> ed, Carlo WA, Chatburn RL, Lough M, eds. Yearbook Medical publishers, Chicago, Illinois, pp 236-259, 1988.
6. Blumer JL and Reed MD (editors). Clinical Pharmacology. Ped Clin NA 36 (no 5): 1989.
7. Bertino JS Jr and Reed MD. Barbiturate and Nonbarbiturate Sedative-Hypnotic Intoxication: An Overview in, Drug Toxicity and Metabolism in Pediatrics, Kacew S, ed, CRC Press, Boca Raton, Florida, pp 221-232, 1990.
8. Reed MD and Blumer JL. Drug-Drug Interactions in Clinical Management of Poisoning and Drug Overdose, 2<sup>nd</sup> ed, Haddad LM and Winchester JF, eds. WB Saunders & Co, Philadelphia, Pennsylvania, pp 458-470, 1990.
9. Reed MD. Drug Formulary in Handbook of Respiratory Care, 2<sup>nd</sup> ed, Chatburn RL and Lough MD, eds, Yearbook Medical Publishers, Chicago, Illinois, 1990.
10. Reed MD and Blumer JL. Bronchopulmonary Infections in Cystic Fibrosis: Pathophysiology and Treatment. Sanders E and Sanders C eds. Physicians and Scientists Publishing Co, Illinois, pp 149-175, 1990.
11. Reed MD. Chapter 70: Calcium Antagonists, pp 352-353 and Chapter 91: Sedative-Hypnotic Drugs, pp 395-396 in Pediatric Emergency Medicine: A Clinician's Guide. Grossman M, Dieckmann RA eds. JB Lippincott Co, Philadelphia, Pennsylvania, 1990.
12. Reed MD. Chapter 92: Parenteral Nutrition, pp 582-592, Chapter 93: Enteral Nutrition, pp 592-611, Chapter 100: Poisonings: General Principles, pp 660-671 and Chapter 107: Theophylline Intoxication, pp 693-698 in A Practical Guide to Pediatric Intensive Care. Blumer JL ed. Mosby Co, St Louis, 1991.
13. Reed MD. Application of Clinical Pharmacokinetics in Infants and Children in Pediatric Pharmacy Practice. Kuhn RJ, Piccoro JJ and Shannon MC eds. University of Kentucky, 1991.
14. Reed MD. Principles of Drug Therapy (Chapter 655), in Nelson Textbook of Pediatrics, 14<sup>th</sup> ed, Behrman RE, Kliegman RM, eds, WB Saunders Co, Philadelphia, Pennsylvania, pp 252-258, 1991.

15. Reed MD. Table 27-3: Drug Dosages in Nelson Textbook of Pediatrics, 14<sup>th</sup> ed, Behrman RE and Kliegman R eds. WB Saunders Co, Philadelphia, Pennsylvania, pp 1827-1844, 1991.
16. Blumer JL and Reed MD. Principles of Neonatal Pharmacology in, Pediatric Pharmacology: Therapeutic Principles in Practice. Yaffe SJ and Aranda JV eds. WB Saunders Co, Philadelphia pp 164-177, 1992.
17. Reed MD, Sutphen JL and Blumer JL. The Clinical Pharmacology of Drugs Used to Modulate Gastrointestinal Function in, Pediatric Pharmacology: Therapeutic Principles in Practice. Yaffe SJ and Aranda JV eds. WB Saunders Co, Philadelphia, Pennsylvania, pp 437-465, 1992.
18. Reed MD and Witte MK. Infections of the Lower Respiratory Tract (Chapter 95) in, Pharmacotherapy: A Pathophysiologic Approach, 2<sup>nd</sup> ed, DiPiro JT, Talbert RL, Hayes PE, Yee GC, Matzke GR, Posey LM eds. Appleton & Lange Publishing Co, Norwalk, Connecticut, pp 1543-1559, 1993.
19. Blackman JA, Reed MD and Roberts CD. Muscle Relaxant Drugs for Children with Cerebral Palsy in The Diplegic Child: Evaluation and Management, Shriner's Hospitals for Crippled Children Symposium. Am Acad Orthopaedic Surgeons, Rosemont, Illinois, pp 229-2349, 1992.
20. Reed MD. Application of Clinical Pharmacokinetics in Infants and Children (Chapter 15), in Pediatric Pharmacotherapy, 2<sup>nd</sup> ed, Kuhn RJ ed, University of Kentucky Press, 1993.
21. Lebovitz DJ and Reed MD. Clinical Pharmacology of Mucokinetic Drugs in, The Pharmacologic Approach to the Critically Ill Patient, 3<sup>rd</sup> ed, Chernow B ed. Williams & Wilkins, Baltimore, Maryland, pp 605-613, 1994.
22. Reed MD, Goldfarb J and Blumer JL. Anti-Infective Therapy (Chapter 14) in, Pediatric Infectious Diseases: Principles and Practice. Jenson HB and Baltimore HA eds. Appleton & Lang, Norwalk, Connecticut, pp 177-273, 1995.
23. Reed MD. Principles of Drug Therapy (Chapter 63) in, Nelson's Textbook of Pediatrics, 15<sup>th</sup> ed. Behrman RE, Kliegman RM and Arvin AM eds. WB Saunders Co, pp 290-298, 1995.
24. Reed MD. Table of Drug Doses in, Nelson's Textbook of Pediatrics, 15<sup>th</sup> ed. Behrman RE, Kliegman RM and Arvin AM eds. WB Saunders Co, pp 2048-2078, 1995.
25. Toltzis P, Witte MK and Reed MD. Lower Respiratory Tract Infections (Chapter 100) in, Pharmacotherapy: A Pathophysiologic Approach, 3<sup>rd</sup> ed, DiPiro JT, Talbert RL, Yee, GC, Matzke GR, Wells BG and Posey LM, eds. Appleton & Lange, pp 1995-2016.
26. Reed MD and Spino M. Clinical Pharmacokinetics: Concepts to Practice in, Treatment of the Hospitalized Patient with Cystic Fibrosis. Orenstein DJ and Stern RC eds. Marcel Dekker, Inc, pp 301-317, 1997.
27. Reed MD and Blumer JL. Pharmacologic Treatment of the Fetus (Chapter 10) in, Neonatal-Perinatal Medicine: Diseases of the Fetus and Infants, 6<sup>th</sup> ed. Fanaroff AA and Martin RJ eds. Mosby Year Book, pp 157-187, 1997.
28. Gal P and Reed MD. Therapeutic Drug Monitoring in the Neonate (Chapter 24) in, Fetal and Neonatal Physiology, 2<sup>nd</sup> ed. Polin RA and Fox WW eds. WB Saunders Co, pp 250-255, 1998.
29. Reed MD and Blumer JL. Drug-Drug Interactions (Chapter 21) in, Clinical Management of Poisoning and Drug Overdose, 3<sup>rd</sup> ed. Haddad LJ, Shannon MW and Winchester JF eds. WB Saunders Co, pp 307-318, 1998.
30. Reed MD and Gal P. Principles of Drug Therapy (Chapter 727) in, Nelson Textbook of Pediatrics, 16<sup>th</sup> ed. Behrman RE, Kliegman RM and Jenson HB eds. WB Saunders, Co, Philadelphia, Pennsylvania, pp 2229-2234, 2000.

31. Reed MD and Gal P. Medications Tables 728-1 through 727-7 in, Nelson Textbook of pediatrics, 16<sup>th</sup> ed. Behrman RE, Kliegman RM and Jenson HB eds. WB Saunders Co, Philadelphia, Pennsylvania, pp 2235-2303, 2000.
32. Reed MD and Blumer JL. Pharmacologic Treatment of the Fetus (Chapter 10) in, Neonatal-Perinatal Medicine: Diseases of the Fetus and Infants, 7<sup>th</sup> ed. Fanaroff AA and Martin RJ eds. Mosby Year Book, pp 167-190, 2001.
33. Neely MN and Reed MD. The Pharmacokinetic Pharmacodynamic Basis of Optimal Antibiotic Dosing (Chapter 305) in, Long SS, Pickering LK and Prober CSB, eds. Principles and Practice of Pediatric Infectious Diseases, 2<sup>nd</sup> ed, Churchill Livingstone, New York, pp 1443-1457, 2003.
34. Reed MD and Blumer J., Anti-Infective Therapy (Chapter 14) in, Pediatric Infectious Diseases: Principles and Practice, 2<sup>nd</sup> ed, Jenson HB and Baltimore RS eds. WB Saunders Co, Philadelphia, Pennsylvania, pp 147-215, 2002.
35. Glover ML and Reed MD. Lower Respiratory Tract Infections (Chapter 106) in, Pharmacotherapy A Pathophysiologic Approach, 5<sup>th</sup> ed, DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM eds. McGraw-Hill, Medical Publishing Co, New York, pp 1849-1868, 2002.
36. Reed MD and Gal P. Principles of Drug Therapy (Chapter 727) in, Nelson Textbook of Pediatrics, 17<sup>th</sup> ed, Behrman RE, Kliegman RM and Jenson HB eds. WB Saunders Co, Philadelphia, Pennsylvania, pp 2427-2432, 2003.
37. Reed MD and Gal P. Medications Tables 728-1 through 728-7 in, Nelson Textbook of Pediatrics, 17<sup>th</sup> ed, Behrman RE, Kliegman RM and Jenson HB eds. WB Saunders Co, Philadelphia, Pennsylvania, pp 2432-2502, 2003.
38. Blumer JL and Reed MD. Principles of Neonatal Pharmacology (Chapter 13) in, Pediatric Pharmacology: Therapeutic Principles in Practice. Yaffe SJ and Aranda JV eds. 3<sup>rd</sup> ed, Lippincott-Williams & Wilkins, Philadelphia, Pennsylvania, pp 146-158, 2005.
39. Reed MD, Aranda JV and Hales BF. Developmental Pharmacology (Chapter 10 Part 1) in, Fanaroff and Martin's Neonatal-Perinatal Medicine: Diseases of the Fetus and Infants, 8<sup>th</sup> ed, Martin, RJ, Fanaroff, AA and Walsh, MC, eds Mosby Elsevier, pp 183-202, 2005.
40. Reed, MD and Blumer, JL, Pharmacologic Treatment of the Fetus (Chapter 10 Part 2) in, Fanaroff and Martin's Neonatal-Perinatal Medicine: Diseases of the Fetus and Infants, 8<sup>th</sup> ed. Martin RJ, Fanaroff AA and Walsh M, eds. Mosby Elsevier, pp 202-229, 2005.
41. Glover ML and Reed MD. Lower Respiratory Tract Infections (Chapter 106) in, Pharmacotherapy A Pathophysiologic Approach, 6<sup>th</sup> ed. DiPiro JT, Talbert RL, Yee GC, Matzke GF, Wells BG, Posey LM eds. McGraw-Hill, Medical Publishing Co, New York, pp 1943-1962, 2005.
42. Gal P and Reed MD. Principles of Drug Therapy (Chapter 57) in, Nelson Textbook of Pediatrics. Kliegman RJ, Behrman RE, Jenson HB and Stanton B eds. WB Saunders Co, Philadelphia, Pennsylvania, 18<sup>th</sup> ed, pp 331-339, 2007.
43. Rogers GC Jr, Condurache T, Reed MD, Bestic M, Gal P, Poisonings (Chapter 58) in, Nelson Textbook of Pediatrics. Kliegman RM, Behrman RE, Jenson HB and Stanton B eds. WB Saunders Co, Philadelphia, Pennsylvania, pp 339-357, 2007.
44. Glover ML and Reed MD. Lower Respiratory Tract Infections (Chapter 111) in, Pharmacotherapy A Pathophysiologic Approach, 7<sup>th</sup> ed. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM eds. McGraw-Hill, Medical Publishing Co, New York, pp 1761-1778, 2007.
45. Neville KA, Blake MJ, Reed MD and Kearns GL. Pediatric Clinical Pharmacology (Chapter 17) in, Pharmacology and Therapeutics: Principles to Practice. Waldman SA, Terzic A eds. Elsevier Publishing, 2009.

46. Blackford M, Glover ML and Reed MD. Lower Respiratory Tract Infections (Chapter 116) in, Pharmacotherapy A Pathophysiologic Approach, 8<sup>th</sup> ed. Dipiro JT, Talbert, RL, Yee, GC, Matzke GR, Wells, BG, Posey LM, eds. McGraw-Hill, medical Publishing Co. New York, pp 1761-1778, 2011.
47. Reed MD and Mattison DR. Treating the Placenta: An Evolving Therapeutic Concept (Chapter 6) in, Clinical Pharmacology During Pregnancy, Mattison D, ed., Elsevier Publishing, New York, pp. 73-87, 2012.
48. Reed, MD, Bestic, M. Developmental Pharmacokinetics: Drug Disposition Relative to Age (Chapter 2) in, Bone Drugs in Pediatrics: Efficacy and Challenges, Klein GL, ed., Springer Publishing, New York, pp. 5-22, 2014.

**Abstracts**

**\*Platform Presentation**

**+Poster Presentation**

1. Reed MD, Vermeulen MW, Boat TF, Stern RC and Cheng PW. Enzymuria Does Not Predict Aminoglycoside-Associated Nephrotoxicity. Cystic Fibrosis Club, Atlanta, Georgia, 1979.
2. Reed MD, Verneulen MW, Boat TF, Stern RC and Cheng PW. Enzymuria Does Not Predict Aminoglycoside-Associated Nephrotoxicity. Ped Res 1979;13:518.
3. Solomon KS and Reed MD. Cyclic Alimentation: An Alternative for Bone Marrow Transplant Recipients, American Society of Hospital Pharmacists, Las Vegas, Nevada, December, 1979.+
4. Halpin TC Jr, Reed MD and Gross S. Pre-Albumin, Albumin and Transferrin in the Assessment of Parenteral Nutrition in Bone Marrow Transplantation. JPEN 1979;3:505.\*
5. Halpin TC, Bertino JS Jr and Reed MD. Use of Intravenous Iron Dextran in Sick Children with Iron Deficiency Anemia. Clin Res 1980;28:237A.
6. Lazarus HM, Reed MD, Blumer JL, Poteat M, Fishman DJ and Herzig RH. Cyclic Intravenous Alimentation During Autologous Bone Marrow Transplantation. American College of Physicians, Kings Island, Ohio, September, 1980.\*
7. Bertino JS Jr, Reed MD, Halpin TC Jr and Lambert PO. Stability and Efficacy of an Extemporaneous Formulation of Parenteral Cholecalciferol. American Society of Hospital Pharmacists, San Francisco, California, December, 1980.+
8. Reed MD and Bertino JS Jr. Chelation Therapy for Childhood Lead Intoxication. American Society of Hospital Pharmacists, San Francisco, California, December, 1980.+
9. Reed MD and Bertino JS Jr. Continuous Morphine Infusion in the Management of Intractable Pain, American Society of Hospital Pharmacists, San Francisco, California, December, 1980.+
10. Halpin TC Jr, Reed MD and Bertino JS Jr. Intravenous Iron-Dextran in Children Receiving TPN for Nutritional Support of Inflammatory Bowel Disease. JPEN 1980;4:600.+
11. Rothstein FC, Reed MD and Halpin TC Jr. Phase I Study: Aggressive Nutritional Management of Children with Inflammatory Bowel Disease. 1980;JPEN 4:600.+
12. Reed MD, Halpin TC Jr, Gross S, Poteat M and Blumer JL. Nutritional Support and Monitoring of Children Undergoing Bone Marrow Transplantation. 1980;JPEN 4:600.+
13. Reed MD, Lazarus HM, Herzig RH, Poteat M and Blumer JL. Intravenous Alimentation Administered in Cyclic Fashion During Bone Marrow Transplantation. Proceedings of the American Society of Clinical Oncology 1981;22:418.
14. Reed MD, Stern RC, Bertino JS Jr and Blumer JL. Pharmacokinetic Evaluation of Trimethoprim-Sulfamethoxazole in Patients with Cystic Fibrosis. Cystic Fibrosis Club Abstracts San Francisco, California, 1981.
15. Aronoff SC, Scoles PV, Reed MD, Myers C, Bertino JS Jr and Blumer JL. Clinical Efficacy and Pharmacokinetics of Moxalactam in Pediatric Skeletal Infections. Ped Res 1981;15:606.

16. Reed MD, Stern RC, Bertino JS Jr, Myers C and Blumer JL. Pharmacokinetic Evaluation of Trimethoprim-Sulfamethoxazole in Patients with Cystic Fibrosis. *Ped Res* 1981;15:500.\*
17. Reed MD, Bertino JS Jr, Aronoff SC, Husak MP, Blumer JL and Speck WT. Efficacy and Pharmacokinetics of Piperacillin Patients with Cystic Fibrosis. 21<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Chicago, Illinois, November 1981, #480.+
18. Rothstein FC, Reed MD and Halpin TC. Visceral Protein Responses in Children with Inflammatory Bowel Disease. American Society of Parenteral and Enteral Nutrition, San Francisco, California, February, 1982.+
19. Rothstein FC, Reed MD and Halpin TC. Prealbumin: A Sensitive Index of Disease Activity in Inflammatory Bowel Disease. *Ped Res* 1982;16:175A.
20. Reed MD, Bertino JS Jr, Myers CM, Husak MP and Blumer JL. The Pharmacokinetics of Moxalactam in Pediatric Patients. *Ped Res* 1982;16:130A.
21. Reed MD, Bertino JS Jr, Myers C and Blumer JL. Piperacillin Pharmacokinetics in Cystic Fibrosis *Ped Res* 1982;16:121A.
22. Reed MD, Bertino JS, Aronoff SC, Myers CM, Speck WT and Blumer JL. Pharmacokinetics of Moxalactam in Children. *Clin Pharmacol Ther* 1982;31:262.+
23. Bertino JS Jr, Reed MD, Myers C and Blumer JL. Piperacillin Pharmacokinetics in Cystic Fibrosis. *Drug Intell Clin Pharm* 1982;16:469-470.\*
24. Rothstein, F, Reed M and Halpin T. Prealbumin: The Most Sensitive Liver Secretory Protein (LSP) for Monitoring Therapy of Childhood Inflammatory Bowel Disease (IBD). *JPEN* 1982.6:584.+
25. Reed MD, Kercksmar CM, Stern RC, Murdell DM and Blumer JL. Ceftazidime in Cystic Fibrosis: Pharmacokinetics and Therapeutic Response. *Clin Pharmacol Ther* 1983;33:256.+
26. Reed MD, ReKate H, Murdell D, Myers C and Blumer JL. Single Dose Plasma and Cerebrospinal Fluid Pharmacokinetics of Ceftriaxone in Children. *Clin Pharmacol Ther* 1984;33:246.\*
27. Reed MD, Kercksmar CM, Myers CM, Stern RC, Murdell DM and Blumer JL. Ceftazidime in Cystic Fibrosis: Pharmacokinetics and Therapeutic Response. *Ped Res* 1983;17:154A.
28. Reed M, Stern R, Ackers I, Murdell D, O'Brien C, Klinger J and Blumer JL. Efficacy and Pharmacokinetics of Cefsulodin-Tobramycin Combined Therapy in Patients with Cystic Fibrosis. *Ped Res* 1983;17:153A.\*
29. Aronoff SC, Reed MD, Murdell DM, O'Brien CA and Blumer JL. Ceftriaxone Therapy in Serious Pediatric Infections. *Ped Res* 1983;17:265A.
30. Reed M, ReKate H, Murdell D, Myers D and Blumer JL. Single Dose Plasma and Cerebrospinal Fluid Pharmacokinetics of Ceftriaxone in Children. *Ped Res* 1983;17:280A.
31. Slaughter RL, Myers CM, Reed MD, Kohli R and Brass C. The Pharmacokinetics of Sulfamethoxazole / Trimethoprim (SMX / TMP) During Peritoneal and Hemodialysis. *Drug Intell Clin Pharm* 1983;17:440.+
32. Reed MD, Stern RC, Acker I, Murdell D, O'Brien C, Klinger J and Blumer JL. The Efficacy and Pharmacokinetics of a Cefsulodin / Tobramycin (C/T) Combination in Patients with Cystic Fibrosis. *Drug Intell Clin Pharm* 1983;17:446.\*
33. Aronoff S, Reed M, Murdell D, O'Brien C and Blumer JL. Ceftriaxone Therapy in Serious Pediatric Infections. Proceedings of the 13<sup>th</sup> International Congress of Chemotherapy, Vienna, Austria, August, 1983.\*

34. Reed M, Stern R, Ackers I, Murdell D, O'Brien C, Klinger J and Blumer JL. Efficacy and Pharmacokinetics of Cefsulodin / Tobramycin Combined Therapy in Patients with Cystic Fibrosis. Proceedings of the 13<sup>th</sup> International Congress of Chemotherapy, Vienna, Austria, August, 1983.\*
35. Blumer JL, Reed MD, Aronoff S and Myers C. CSF Penetration and Pharmacokinetics (PK) of Ceftazidime (CZ) in Children with Bacterial Meningitis (M). 23<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Las Vegas, Nevada, October, 1983, #830.+
36. Reed M, Murdell D, O'Brien C, Aronoff S and Blumer J. Efficacy and Safety of Ceftazidime (CAZ) in Serious Pediatric Infections. 23<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Las Vegas, Nevada, October, 1983, #78.\*
37. Reed MD, Stern RD, O'Brien CA, Myers CM and Blumer JL. Efficacy and Pharmacokinetics of Imipenem / Cilastatin in Cystic Fibrosis. Clin Pharmacol Ther 1984;5:268.+
38. Blumer JL, Reed MD, Myers CM and Stern RC. Steady State Transplacental Pharmacokinetics of Tobramycin. Clin Pharmacol Ther 1984;35:228.\*
39. Weissman BM, Horowitz SJ, Myers CM, Reed MD and Blumer JL. Midazolam (M) Sedation for Computerized Tomography (CT) in Children (C). Ped Res 1984;18:162A.
40. Reed MD, Rothstein FC, Myers CM, O'Brien CA and Blumer JL. Rational Dosing of Ranitidine® in Pediatric Ulcer Disease (UD). Ped Res 1984;18:159A.
41. Dickinson CJ, Aronoff SC, Stern RC, Reed MD and Blumer JL. Modulation of Chloramphenicol (C) Bioavailability (F) by Pancreatic Enzyme Replacement (PER) in Cystic Fibrosis. Ped Res 1984;18:151A.\*
42. Reed MD, Stern RC, O'Brien CA, Myers CM and Blumer JL. Efficacy and Pharmacokinetics of Imipenem / Cilastatin in Patients with Cystic Fibrosis. Drug Intell Clin Pharm 1984;18:512.+
43. Yamashita TS, Reed MD, Blumer JL and Lee HL. Numerical Solutions for the AUC and AUMC Under Noncompartmental Pharmacokinetic Models. The XII<sup>th</sup> International Biometrics Conference, Tokyo, Japan, September, 1984.+
44. Yamashita TS, Reed MD, Lee HL and Blumer JL. Noncompartmental Pharmacokinetic Evaluation Following Multidose Administration. American Statistical Association Joint Statistical Meeting, Philadelphia, Pennsylvania, August, 1984.+
45. Lee HL, Reed MD, Yamashita TS and Blumer JL. Time Required to Achieve Therapeutic Range in Michaelis-Menten Kinetics. American Statistical Association Joint Statistical Meeting, Philadelphia, Pennsylvania, August, 1984.+
46. Weissman BM, Horowitz SJ, Myers CM, Reed MD and Blumer JL. Midazolam Sedation for Computed Tomography in Children: Pharmacokinetics and Pharmacodynamics. Ann Neurol 1984;16:410.+
47. Blumer JL, Stern RC and Reed MD. Efficacy and Safety of Ceftazidime (CAZ) for Pseudomonas cepacia (PC) Infections in Cystic Fibrosis (CF). 24<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, DC, October, 1984, #851.+
48. Reed MD, Stern RC, Myers CM, Yamashita TS and Blumer JL. Randomized, Double-Blind Evaluation of Piperacillin (P) Therapy in Cystic Fibrosis (CF). 24<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC, October, 1984, #849.+
49. Blumer JL, Stern RC, Klinger JD and Reed MD. Ceftazidime Therapy for Cystic Fibrosis Patients with Pseudomonas Susceptible to No Other Drug(s). Cystic Fibrosis Club Abstracts, Anaheim, California, 1985.+

50. Reed,MD, Stern RC, Klinger JD and Blumer JL. A Comparative Evaluation of Cefsulodin Plus Tobramycin Versus Ticarcillin Plus Tobramycin for Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis. Cystic Fibrosis Club Abstracts, Anaheim, California, 1985.\*
51. Blumer JL, Stern RC, Myers CM, Klinger JD and Reed MD. Pharmacokinetics (PK) and Pharmacodynamics (PD) of Ciprofloxacin (CIP) in Cystic Fibrosis (CF). Ped Res 1985;19:168A.
52. Blumer JL, Reed MD, Rothstein FC, Myers CM and O'Brien CA. Rational Dosing of Ranitidine® in Pediatric Ulcer Disease (UD). Ped Res 1985;19:168A.\*
53. Reed M, Stern RC, Klinger JD and Blumer JL. Cefsulodin(C) in Cystic Fibrosis: Pharmacokinetics (PK) and Clinical Efficacy Compared with Ticarcillin (Ti) when Combined with Tobramycin (T) .Proceedings of the 14<sup>th</sup> International Congress of Chemotherapy, Kyoto, Japan, June, 1985.\*
54. Blumer JL, Stern RC, Myers CM, Klinger JD and Reed MD. Pharmacokinetics (PK) and Pharmacodynamics (PD) of Ciprofloxacin (CIP) in Cystic Fibrosis (CF). Proceedings of the 14<sup>th</sup> International Congress of Chemotherapy, Kyoto, Japan, June, 1985.\*
55. Reed M, Stern R, Capretta T and Blumer J. Ceftazidime (CAZ) Dose Ranging: A Randomized Double-Blind Evaluation in Patients (PTS) with Cystic Fibrosis (CF) . 25<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Minneapolis, Minnesota, October, 1985, #173.+
56. Huang ME, Weiner JH, Hulman SE, Kliegman RM, Reed MD and Blumer JL. Pharmacokinetic (PK) Basis for Vancomycin (VAN) Dosing in Premature Infants Ped Res 20:204A, 1986.\*
57. Reed MD, Cunningham MM and Hill JH. Accidental Hydrocarbon (HC) Ingestion: Lack of Need for Emergency Room (ER) Examination. Ped Res 1986;20:259A.\*
58. Blumer JL, Stern RC, Yamashita TS and Reed MD. Evaluation of an Acute Clinical Scoring System (ACES) for Cystic Fibrosis (CF) Patients Receiving Antimicrobial Therapy. Ped Res 1986;20:470A.
59. Reed MD, Stern RC, Capretta TM and Blumer JL. A Randomized Double-Blind Evaluation of Ceftazidime (CAZ) Dose Escalation in Cystic Fibrosis (CF) patients (PTS) . Ped Res 1986;20:477A.
60. Reed MD, Stern RC, Capretta TM and Blumer JL. A Randomized Double-Blind Evaluation of Ceftazidime Dose Escalation in Cystic Fibrosis Patients. Cystic Fibrosis Club Abstracts, Bethesda, Maryland, 1986.\*
61. Blumer JL, Stern RC, O'Brien C and Reed MD. Altered Pharmacokinetics and Pharmacodynamics of Ciprofloxacin in Cystic Fibrosis. Cystic Fibrosis Club Abstracts, Bethesda, Maryland, 1986.+
62. Blumer J, Weissman B, Horowitz S, Myers C and Reed M. Midazolam Sedation for Computerized Tomography (CT) in Children Pharmacokinetics and Pharmacodynamics. III Work Conference on Clinical Pharmacology and Therapeutics, Stockholm, Sweden, 1986.+
63. Baley J, Myers C, Reed M and Blumer J. Pharmacokinetics (PK) of Amphotericin B (AB) and 5-Flucytosine (5 FC) in Neonates. 26<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, New Orleans, October, 1986, #606.+
64. Reed M, Kliegman R and Blumer J. Pharmacokinetic (PK) Basis for Vancomycin (Van) Dosing in Premature Infants. 26<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, New Orleans, October, 1986, #607.+

65. Blumer J, Reed M, Lemon E and Crenshaw D. Comparative Efficacy and Safety of Cefixime (C) and Amoxicillin (A) in the Treatment of Acute Otitis Media in Children .26<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, New Orleans, October, 1986, #871.+
66. Reed MD, Stern RC, Myers CJ and Blumer JL. Pharmacokinetics and Pharmacodynamics of Ciprofloxacin in Cystic Fibrosis. Clin Pharmacol Ther 1987;41:19. +
67. Reed MD, Kliegman RM, Yamashita TS and Blumer JL. The Pharmacokinetics of Imipenem and Cilastatin in Premature Infants. Clin Pharmacol Ther 1987;41:214.\*
68. Reed MD, Kliegman RM, Yamashita TS and Blumer JL. The Clinical Pharmacology of Imipenem (IMP) and Cilastatin (Cil) in Premature Infants. Ped Res 1987;21:241A.\*
69. Forrest A, Drusano G, Reed M and Blumer J. Optimal Sampling Theory (OST) and Adaptive Study Design. 27<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, New York, New York, October, 1987, #447.+
70. Reed MD, Goldfarb J and Crenshaw D. Lack of Correlation Between Clinical Response and Sputum Quantitative Cultures in Patients with Cystic Fibrosis. 27<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, New York, New York, October, 1987, #798.\*
71. Witte MK, Lough M and Reed MD. Energy Expenditure in the Pediatric Intensive Care Unit: A Critical Reappraisal. JPEN 1988;12(Suppl):5S.\*
72. Reed MD, Gooch WM, Swenson E and Blumer JL. The Pharmacokinetics (PCK) of Ceftizoxime in Infants 1-6 Months of Age. Clin Pharmacol Ther 1988;43:155. +
73. Grasela TH, Guay DR, Awni WM, Rybak MJ, Nahata MW, Reed MD and Matzke GR. Population Pharmacokinetic Parameters of Vancomycin. Clin Pharmacol Ther 1988;43:132.+
74. Reed MD, Goldfarb J and Blumer JL. Disparate Pharmacokinetics (PK) of Ticarcillin (T) and Clavulanic Acid (C) Following Timentin Administration in Children. J Clin Pharmacol 1988;28:926.+
75. Reed MD and Blumer JL. Dose-Finding Study of Imipenem Cilastatin in Premature Infants. J Clin Pharmacol 1988;28:927.+
76. Besunder JB, Reed MD, Yamashita TS and Blumer JL. D-penicillamine Pharmacokinetics in Lead Intoxicated Children. Clin Pharmacol Ther 1989;45:134.\*
77. Blumer JL, Ruggierie DP, Witte MK, Weise KL, Pettigrew A, Yamashita TS and Reed MD. Polymorphic Clearance (Cl) of Dopamine (DA) and Dobutamine (DB) in Children. Clin Pharmacol Ther 1989;45:140.+
78. Reed MD, Yamashita TS and Blumer JL. The Clinical Pharmacology of Teicoplanin in Older Infants and Children. Clin Pharmacol Ther 1989;45:140.+
79. Besunder JB, Reed MD, Fedak MJ, Yamashita TS and Blumer JL. D-penicillamine Pharmacokinetics and Pharmacodynamics in Lead Intoxicated Children. Ped Res 1989;25:65A.\*
80. Blumer JL, Ruggierie DP, Weise KL, Thompson S, Pettigrew A, Yamashita TS and Reed MD. Exogenous Catecholamine (C) Pharmacokinetics (PK) in Children (K) Ped Res 1989;25:65A.\*

81. Reed,MD, Kearns GL, Jacobs RF, Yogev R, Ardite M, Chang-Lin C and Blumer JL. The Pharmacokinetics (PK) of Ceftibuten (CFB) Suspension in Infants and Children. 29<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Houston, Texas, September, 1989, #1224.+
82. Reed MD, Gooch WM, Swenson EM, Minton SD, Yamashita TS and Blumer JL. The Ontogeny of Ceftizoxime Disposition During the First 6 Months of Life. 29<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Houston, Texas, September, 1989, #1231.+
83. Reed MD, Yamashita TS and Blumer JL. The Clinical Pharmacology of Ticarcillin (T) and Clavulanate (C) in Children Undergoing Cardiac Surgery. 29<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Houston, Texas, September, 1989, #1233.+
84. Kearns GL, Castell HB, Taylor BJ, Wells TG, Myers CM and Reed MD. Pharmacokinetics (PK) of Metoclopramide (MC) in Neonates with Gastroesophageal Reflux (GER). *Ped Res* 1991;29:61A.\*
85. Reed MD and Blumer JL. Ethanol (ETOH) Teratogenesis in the American Sea Urchin (*Arbacia punctulata*) Embryo (SUE). *Pharmacologist* 1991;33:163.+
86. Marx CM, Lebovitz DJ, Blumer JL and Reed MD. Preliminary Evaluation of Propofol Monotherapy for Sedation of Mechanically Ventilated Children. *Pharmacotherapy* 1992;12:226.+
87. Reed MD and Marx CM. Ondansetron: Optimal Antiemetic Therapy for the Poisoned Patient. *Vet Human Toxicol* 1992;34:336.+
88. Reed MD, Kearns G, Jacobs R, Yamashita T, Thompson S, Gooch W, Yogev R, Williams K and Blumer J. Dose Ranging and Pharmacokinetic (PK) Evaluation of Meropenem (M) in Infants and Children. 32<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Anaheim, California, October, 1992, #1230.\*
89. Goldfarb, J, Reed, M, Yamashita, T, Lemon, E and Blumer, J, Pharmacokinetic (PK) and Dose escalation Study of Piperacillin (P) / Tazobactam (T) in Infants and Children 32<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Anaheim, California, October, 1992, #1229.\*
90. Blumer JL, Goldfarb J, Yamashita T, Lemon E, Reed MD. Pharmacokinetic (PK) and Dose Escalation Study of Piperacillin (P) / Tazobactam (T) in Infants and Children. *Clin Pharmacol Ther* 1993;53:146.+
91. Marx CM, Lebovitz DJ, Blumer JL and Reed MD. Preliminary Evaluation of Propofol (P) Monotherapy for Sedation of Mechanically Ventilated (MV) Children (C). *Clin Pharmacol Ther* 1993;53:146.+
92. Reed MD and Blumer JL. Ethanol (ETOH) Teratogenesis in the Sea Urchin (SU) Embryo (E). *Clin Pharmacol Ther* 1993;53:148.+
93. Reed MD, Farrar HC, Marx CM, Kyllonen K, Sullivan J and Blumer JL. Monitoring Serum Vancomycin (V) Concentrations: To Be or Not To Be! *Clin Pharmacol Ther* 1993;53:149.+
94. Reed M, Marx C, Yamashita T, Myers C and Blumer J. Integrated Pharmacokinetic (PK)-Pharmacodynamic (PD) Evaluation of Propofol in Critically Ill Mechanically Ventilated Infants. *Can J Physiol Pharmacol* 1994;72(Suppl1):205.+
95. Blumer JL, Reed MD, Lemon E, Knupp CA, Leonard GA and Veazey JM Jr. Pharmacokinetics (PK) of Cefepime in Pediatric Patients Administered Single and Multiple 50 mg/Kg Doses Q8hr by the Intravenous (IV) or Intramuscular (IM) Route. 34<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Orland, Florida, October 1994, #A69.+

96. Reed MD, Yamashita TS and Blumer JL. Ticarcillin (T) / Clavulanate (C): Critical Reassessment of Pediatric (P) Dose Requirements. *Clin Pharmacol Ther* 1995;57:208.+
97. Glover ML, Blumer JL and Reed MD. Propofol Facilitated Extubation: A Sedative Weaning Schedule for Mechanically Ventilated Pediatric Patients. *Clin Pharmacol Ther* 1996;59:145.+
98. Reed MD, Yamashita TS and Blumer JL. The Clinical Pharmacology of Cefepime in Infants and Children. *Pharmacotherapy* 1996;16:508, +
99. Reed M, Yamashita T and Blumer J. Pharmacokinetic (PK)-Pharmacodynamic (PD) Determination of Propofol (P) Dosing in Critically Ill, Mechanically Ventilated (MV) Pediatric Patients (Pts). *Clin Pharmacol Ther* 1997;61:210.+
100. Reed M, Yamashita T and Blumer J. Pharmacokinetic (PK)-Based Ticarcillin (T) Clavulanate (C) Dosing in Infants, Children and Adults. *Clin Pharmacol Ther* 1997;61:210.+
101. Smith P, Reed M, Lebovitz D, Yamashita T and Blumer J. Single Dose (SD) Pharmacokinetics (PK) of Terbutaline (T) in Pediatric Patients with Status Asthmatics. *Clin Pharmacol Ther* 1997;61:211.+
102. Kearns GL, Reed MD and Blumer JL. Metoclopramide (MET) Pharmacokinetics (PK) in Neonates. *Clin Pharmacol Ther* 1997;61:210.+
103. Kearns GL, Bradley JS, Reed MD and Vincent J. Trovafloxacin Pharmacokinetics in Infants and Children. 37<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, October 8, 1997.+
104. Reed MD, Kaye C, Allen AI and Moonsammy G. Pharmacokinetic / Pharmacodynamic (PK/PD) Determinations of Ticarcillin / Clavulanate Dosage Regimens. 37<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, October 8, 1997.+
105. Reed, M, Kaye, C, Allen, A, Davy, M and Fowles, S, Clinical Pharmacology and Dose Recommendations for a New Intravenous (IV) Formulation of Amoxicillin / Clavulanate (A/C) 38<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, California, September 27, 1998.+
106. Reed M, Blumer J and Moonsammy G. T/C Pediatric Collaborative Study Group Safety and Efficacy of Ticarcillin / Clavulanate (T/C) in the Treatment of Hospitalized Pediatric Patients with Severe Infections. 38<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California; September 25, 1998.+
107. Reed M, Moonsammy G, Kaye C, Allen A and Fowles S. A Novel Twice Daily Amoxicillin Tablet: Pharmacokinetic-Pharmacodynamic (PK/PD) Basis of Dose Determination. 36<sup>th</sup> Annual Meeting, Infectious Diseases Society of America, Denver, Colorado, November 14, 1998.+
108. Reed M, Moonsammy G and Blumer J. Safety, Efficacy and Pharmacokinetic-Based Dosing of Ticarcillin / Clavulanate in Hospitalized Pediatric Patients. *Int Pharm Abst* 1998;35:2297.
109. Farrar H, Reed M, O'Riordan MA, Myers C and Blumer JL. Randomized Double-Blind (DB) Study of Morphine (M) vs Fentanyl (F) Sedation in Mechanically Ventilated (MV) Pediatric Patients (Pts). *Clin Pharmacol Ther* 2001;69:P21.+
110. Blumer JL, Drusano GL, Kaplan EL and Reed MD. Pharmacokinetic (PK) Variability Explains the high Microbiological Failure Rate for Single Dose Ceftriaxone (CTX) for Group A Streptococcal Pharyngitis (GPS). *Clin Pharmacol Ther*, 2001;69:P19.+
111. Reed MD, Stern RC, O'Riordan MA, Myers CM and Blumer JL. The Clinical Pharmacology of Intravenous (IV) Colistin (C) in Patients (PTS) with Cystic Fibrosis (CF). *Clin Pharmacol Ther* 2001;69:P80.\*

112. Reed M, Findling R, Beryl K, van den Heusel J and Blumer J. Single-Dose Pharmacokinetics (PK) of Mirtazapine (M) and its Primary Metabolite (Met) in Depressed Children. Clin Pharmacol Ther 2002;71:P41.
113. Reed M, Findling R, Greenhil, L, Salle, FR, Conners K and Blumer J. Pharmackinetics (PK), Effectiveness (E) and Tolerability (TO) of Transdermal Selegiline (STS) in Children (C) and Adolescents (A) with Attention Deficit Hyperactivity Disorder (ADHD). Clin Pharmacol Ther 2003;73:28.\*
114. Reed MD, Findling RL, Capparelli EV, O’Riordan MA and Blumer JL. A Population Pharmacokinetic (POP-PK) Model of Steady –State (SS) Paroxetine (PXT) in Depressed Children (C) and Adolescents (A). J Clin Pharmacol 2003;43:1026.+
115. Reed MD Konstan M, O’Riordan MA and Blumer JL. Pharmaacokinetics (PK) and Absolute Bioavailability (F) of Linezolid (L) in Cystic Fibrosis (CF). Clin Pharmacol Ther 2005;77:P39.+
116. Jafri HS, Vergara R, Cafiero S, Somers CC, Olsen K, Reed MD, Capparelli EV, McCracken GH and Hardy RD. Azithromycin for the Treatment of Experimental Ureaplasma urealyticum Pneumonia. 46<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, California, September 27-30, 2006.+
117. Capparelli E, Reed MD, van den Anker J, Blumer J, Damonoske C and Bradley J. Developmental Change in Cefepime Pharmacokinetics – Renal Clearance Maturation from Infancy Through Adolescence. J Clin Pharmacol 2006;46:1090. +
118. Sedowsky DW, Reed MD, O’Riordan MA, Duffy LB, Waites KB and Novy MJ. Azithromycin (AZI) Dose-Finding Study for Treatment of Ureaplasma Intra Amniotic Infection (IAI) in Rhesus Monkeys. Reproductive Sci 2007;24(Suppl):30.
119. Bonny AE, Mesiano S, Kaufman B, O’Riordan MW, Reed M, Blumer J and Cromer B. Early Weight Gain in Adolescents on Depot Medroxyprogesterone Acetate: Have We Been Ignoring a Biologic Mechanism? N Amer Soc Ped Adoles Gyn, 2010. +
120. Brantmer JS, Badawy HT, Sieracki B, Klein S, Wagers PO, Youngs, WJ, Kraynack N, Reed MD and Milstead A. The Influence of Mucin and Synthetic Cystic Fibrosis Medium on the In Vitro Bioactivity of Silver Carbene Complexes and selected Antimicrobials, International Conference on Antimicrobial Agents and Chemotherapy. C-1417 September 2014+
121. (b) (6) Reed MD. (b) (6) submitted
122. (b) (6) Reed M, (b) (6), submitted

**Editorial Correspondence**

1. Reed MD and Ball, WD. Pharmacokinetics of Tobramycin, J Infect Dis 1978; 138:278 (Letter).
2. Sher TH, Blumer JL, Bertino JS Jr and Reed MD. Risks of Theophylline Therapy in Asthma. J Pediatr 1983;98:678 (Letter).
3. Reed MD and Blumer JL. Hypoprothrombinemic Potential of Moxalactam. Clin Pharm 1982; 1:305 (Author Reply).
4. Blumer JL and Reed MD. Treatment of Cystic Fibrosis with Trimethoprim-Sulfamethoxazole. J Pediatr 1984;105:680 (Author Reply).
5. Reed MD. Antimicrobial Therapy for Newborns, 2<sup>nd</sup> ed Clin Pharm 1984; 3:436 (Book Review).
6. Reed MD. Pediatric Therapeutic Newsletter. Drug Intell Clin Pharm 1986; 20:993-994 (Book Review).

7. Reed MD. American Academy of Pediatrics Report on Meningitis Published. Clin Pharm 1987;6:103, (Letter).
8. Reed MD. Handbook of Pharmacokinetics Including Clinical Applications, 3<sup>rd</sup> edition. Ther Drug Monitor 1987;9:366 (Book Review).
9. Reed M. Oral Activated Charcoal Therapy. Am J Emerg Med 1988;6:318 (Letter).
10. Reed MD. Problems in Pediatric Drug Therapy, 2<sup>nd</sup> ed. Drug Intell Clin Pharm 1988;22:508 (Book Review).
11. Reed MD. Children Are Real People Too. DICP Ann PHarmacother 1991;25:559 (Letter).
12. Reed MD. Ondansetron as an Antiemetic. Br J Clin Pharmacol 1992;34:144 (Letter).
13. Reed MD. Pediatric Dosage Handbook. Am J Hosp Pharm 1993;50:562-565 (Book Review).
14. Marx CM and Reed MD. Comment Sedative Efficacy of Midazolam in a Pediatric ICU. Ann Pharmacother 1993;27:1543-1544 (Letter).
15. Reed MD. The Treatment of Epilepsy: Principles and Practice. J Pharm Technol 1995;11:6-7 (Book Review).
16. Reed MD and Blumer JL. Propofol Bashing: The Time to Stop is Now! Crit Care Med 1996;24:175-177 (Letter).
17. Reed MD. The Handbook of Psychiatric Drug Therapy for Children and Adolescents. Am J H-S Pharm 1996;53:2766 (Book Review).
18. Kearns GL and Reed MD. Immediate Action Needed to Improve Labeling of Prescription Drugs for Pediatric Patients. Ann Pharmacother 1997;31:249-251 (Letter).
19. Reed MD. High-Dose Amoxicillin in New Guidelines for Treatment of Otitis Media in Children. Am J Health-Syst Pharm 1999;56:2351 (Letter).
20. Ten Eick AP and Reed MD. Possible Digoxin-Azithromycin Interaction in a Child. Clin Drug Investigation 2001;21:233-234 (Author Reply).
21. Kociancic T, Reed MD. Acetaminophen Intoxication and Length of Treatment: How Long is Long Enough? – A Comment. Pharmacotherapy, 2004;24:694-696 (Author Reply).
22. Reed MD. Minor Illness or Major Disease? The Clinical Pharmacist in the Community, 4<sup>th</sup> ed, Clin Pharmacol Ther 81:474-475 (Book Review).

### **Editorial Responsibilities**

#### **Editorial Boards – Active**

Clinical Therapeutics	2005 – present, Editorial Board
Journal of Clinical Pharmacology	2005—present, Associate Editor 1997 – 2005, Editorial Review Board 1996 – 1997, Referee
Journal of Pediatric Pharmacology and Therapeutics	1996 – present, Editorial Review Board
Therapeutic Drug Monitoring	1990 – present, Editorial Board 1982 – 1990, Referee

eJournal American College of Osteopathic Pediatricians 2009 – present, Editorial Board

Pediatric Critical Care Medicine 2014 – present, Editorial Board

Editorial Board – “Retired”

Annals of Pharmacotherapy 1989 – 2004, Column Editor, Pediatrics  
1985 – 1989, Chairman, Editorial Advisory Board – Pediatrics  
1984 – 1985, Editorial Advisory Board – Pediatrics  
1983 – 1984, Referee

Antimicrobial Agents and Chemotherapy 1995 – 2002, Editorial Board  
1988 – 1994, Referee

Biology of the Neonate 1995 – 2002, Editorial Board

Chemotherapy 2000 – 2011, Editorial Board

Current Therapeutic Research 1999 – 2004, Editorial Board

Developmental Pharmacology and Therapeutics 1988 – 1995, Editorial Board  
1986 – 1988, Referee

International Journal of Antimicrobial Agents 1990 – 1998, Editorial Board

Journal of Infectious Disease Pharmacotherapy 1998 – 2001, Editorial Review Board

Neonatal Pharmacology Quarterly 1991 – 1994, Editorial Board

Reviewer – Active

Archives of Diseases in Childhood 2011 – Present, Referee

Bone Marrow Transplantation 2014 – Present, Referee

British Journal of Clinical Pharmacology 2013 – Present, Referee

Clinical Drug Investigation 2009 – Present, Referee

Clinical Pharmacokinetics 2004 – Present, Referee

Clinical Pharmacology and Therapeutics 2005 – Present, Referee

Current Therapeutic Research 1994 – Present, Referee

Clinical Toxicology 2006 – Present, Referee

Critical Care Medicine 1999 – Present, Referee

Drug Metabolism and Disposition 1995 – Present, Referee

Drugs 1996 – Present, Referee

Hospital Pharmacy 1989 – Present, Referee

Journal of Antimicrobial Chemotherapy	2001 – Present, Referee
Journal of Clinical Microbiology	2005 – Present, Referee
Journal of Clinical Psychopharmacology	2008 – Present, Referee
Journal of Pediatrics	1990 – Present, Referee
Molecular Pharmacology	2006 – Present, Referee
Pediatric Critical Care Medicine	2007 – Present, Referee
Pediatric Infectious Diseases Journal	2004 – Present, Referee
Pediatrics	1987 – Present, Referee
Pediatric Drugs	2000 – Present, Referee
Pharmacotherapy	1988 – Present, Referee
The Pharmacogenomics Journal	2012 – Present, Referee
The AAPS Journal	2012 – Present, Referee
Therapeutic Apheresis and Dialysis	2014- Present, Referee
<u>Reviewer – Inactive</u>	
American Hospital Formulary Service	1985 – 1995, Referee
American Journal of Hospital Pharmacy	1982 – 1995, Referee
Clinical Pharmacy	1982 – 1994, Referee
Heart & Lung: The Journal of Critical Care	1992 – 1998, Referee
Journal of Clinical Pharmacy and Therapeutics	1992 – 1998, Referee
Journal of Toxicology Clinical Toxicology	1995 – 1998, Referee
Life Sciences	2000 - 2003, Referee
New England Journal of Medicine	2000 – 2003, Referee
Antimicrobial Agents & Chemotherapy	2002 – 2010, Referee
Clinical Infectious Diseases	2004 – 2010, Referee